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JEFFERY P. LANGER: Well, good morning everyone. [T]hank you all for 
joining us at the IIPCC’s third annual event here at our nation’s capital. My name 
is Jeffery Langer, I am an executive member with the IIPCC. Let me start by 
thanking our sponsors, the gentlemen from TechInsights. Once again, 
TechInsights has offered us financial support for this and it really is the lifeblood 
for our work here in the nation’s capital. This is the third year they have done it. 
Unfortunately, Art Monk, who is a close colleague of IIPCC, is unable to make 
it this year, but he sent this gentleman and his proxy so thank you very much. I 
really appreciate all the work that you guys do and all the support you have given 
us over the years. I would also like to recognize the Catholic University of 
America, the law school, this is the second year [that] we will be publishing 
transcripts of the proceedings that go on here today. Next, I would also like to 
thank PBEC, which is a long-term collaborator with us at the IIPCC. For those 
of you that do [not know] PBEC, this is the Pacific Basin Economic Council 
based out of Hong Kong. IIPCC actually started in Hong Kong and there has 
been long-term collaboration and work with that organization. So, we thank 
them. And finally, I would like to sincerely thank Senator Chris Coons and his 
staff, they have helped us every year we have come here for this program, with 
logistics and preparing rooms. 
For those of you that are not familiar with the IIPCC, this is short for the 
International Intellectual Property Commercialization Council. It was founded 
in 2013 and it is a global, non-profit, non-partisan organization, really focused 
on driving conversations about innovation and commercialization of innovation. 
Of course, at the cornerstone of that is intellectual property, but we really try and 
look at this as a holistic system and seek to find ways for different parties that 
are involved in this to work together and develop and commercialize this 
innovation. The key of this is really human growth and development. Ideally, 
this commercialization and innovation takes place in a way to improve the living 
standard in societies worldwide. 
So, just a couple of notes on IIPCC, since our founding in 2013, we have 
expanded rapidly. [While we have many] international offices, I would like to 
highlight some of our newest members: the people in Brisbane, they just started 
this year; [the people in] the Tokyo office, which was just recently established; 
[and the members in] Osaka. Continuing with our theme of innovation, [I would 
also like to recognize] the move by the previous IIPCC Hong Kong that is now 
going be adopting the greater bay area chapter that will incorporate Southern 
China, Hong Kong, Macau and other countries in that area. If I could also note 
too, there are a number of IIPCC folks that have come in from international 
chapters today. We have representatives from Hong Kong, from the Toronto 
chapter, and in the U.S., we have folks here from New York, as well as San Jose. 
We also have somebody here from Korea. We also benefit from a fantastic board 
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and a number of people that work very hard behind the scenes to help guide the 
IIPCC’s mission. We are very fortunate to have a number of the people on our 
board [here] today including Professor Carl Schramm, who will be speaking on 
one of the later panels. [We also have] Judge Randall Rader, who many people 
in this room know, who will be giving the closing remarks, and Johnson Kong 
is here from Hong Kong. Unfortunately, David Capos was supposed to be here 
as well to give opening remarks, but he has been called away to something else 
so I will be taking over that role. 
So, for some opening comments, I was really thinking about what we were 
thinking about when we were conceiving this conference. For those of you that 
have attended our conferences in the past, we have been much more focused on 
intellectual property laws specifically, and our panels have really focused on 
U.S. [laws and what they] look like in comparison to rules and regulations in 
other parts of the world. [There has] been much more of a legal focus. This year, 
we really wanted to take a step back and start to talk about innovation in a much 
more holistic manner, and while IP is a cornerstone for a lot of this, the 
innovation and commercialization of that innovation are other parts of the 
ecosystem that also require some attention. One of the things that drove this 
thinking for me was a conversation I recently had with a former classmate. We 
were talking about the speed of innovation and how that has really [been] 
altering what innovation looks like. As background, he is working for Governor 
Kasich’s office in the workforce transformation office, where they are looking 
at what educational policy should look like for Ohio as we are moving through 
all these dramatic technical changes. You know, what is going to be the impact 
of autonomous vehicles as those start to ripple through the commercial 
ecosystem, and how are we going to train people in their K–12 years and then in 
their college years for these on-going and increasingly rapid transformations to 
technology? 
I think as humans too, we are not particularly good at keeping in mind how 
fast some of these changes are taking place. If we think about—and I know this 
is two-year-old data—but if we talk about mass adoption of airlines, this was 
only really sixty-eight years ago; telephones, only fifty years ago; radio, thirty-
eight years ago; television, twenty-two years ago. Then if we start looking at 
Pokémon GO and Angry Birds, which really involve only a two-year-old 
technology, these are very commercial, consumer-oriented things [that have 
been widely adopted very quickly]. So, as the panels are coming up today, I 
think it is critical that we think about innovation, the speed of it, and how that is 
going to change while we are considering the state we are in today. So, with that, 
let me introduce the first panel, and Everardo, I will let you introduce the 
panelists. 
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EVERARDO RUIZ: My name is Everardo Ruiz and I am actually in IIPCC 
Seattle, so I took a nice red-eye [flight] to get here. At the same time, the reason 
I did that was because it just seemed like it was important. There is a lot of 
discussion around innovation with almost zero facts presented, right? “Oh, it 
happens this way. It does not happen this way. It happens this way.” No data, 
right? Well it turns out, data does exist, and it is studied. So really, this panel is 
boots on the ground and it describes this kind of half-life of technology 
decreasing so rapidly and things just happening so quickly in this internet era 
that we live in. How do we actually innovate? How does it actually occur? Why 
does it happen in the United States? What works? What might be some 
challenges? How do you make it sustainable so that it is here, because it can 
happen all over the world, right? So [this idea and these questions are really] 
what drew me to this theme of boots on the ground. 
I would say there are really three groups of speakers. One is focused on 
realities. What does the data say when questions are raised? We have a speaker 
who will be handling that from Georgetown. We will also be focusing on what 
the government is doing to promote innovation. What does the view look like if 
you are actually sitting inside the National Institute of Standards and Technology 
(“NIST”)? [NIST] is something which a lot of people do not really understand, 
but it has a huge reach; it is not just looking for magnetic monoparticles or 
something like that. I mean it really is important, as is the Small Business 
Administration (“SBA”). Finally, the other way to get the view of the war is to 
go talk to the soldiers, to the people who are actually fighting it. So, we have 
several speakers from their specific companies and [you will see the current 
world is] very interdisciplinary. It is a very different world than it was back when 
the airplane was invented. So, how does that change things, right? Again, [we 
will look at] what is working, what is not working. Then, we will have a 
[question and answer portion] at the end to take questions since time is short. 
This will allow [the questions] to be pooled and for us to maybe get some 
interaction between the speakers. 
First, let us talk about innovation realities. From Georgetown University Law 
Center, we have Neel Sukhatme, who is an associate professor of law [with a] 
JD cum laude from Harvard Law, a PhD in economics from Princeton, [and who 
is a] Thomas Alva Edison Visiting Fellow at the U.S. Patent and Trademark 
Office. So, data, he has. Let us go ahead and invite him up to the platform for 
some third-party observations. 
PROFESSOR NEEL SUKHATME: Thank you Everardo. It is a pleasure to 
be here. My name is Neel Sukhatme. As Everardo mentioned, I am a professor 
at Georgetown Law where I teach patent law, corporate finance, and law in 
economics, among other subjects. I have been interested in patents and 
innovation for a long time. I started off my career as a patent prosecutor right 
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after I earned my degree in computer engineering. After that, I went to law 
school and then practiced as a patent litigator and also as a federal court clerk. I 
was really interested in trying to do empirical analysis in this area, so then I 
decided to go back [to school] and [earn] my PhD in economics, where my 
dissertation research focused on the economics of innovation and patenting. I 
am also a co-founder of a music technology start-up company, Spindrop, so I 
have worked on patent issues on that end [as] an entrepreneur and I have just 
started at the U.S. Patent and Trademark Office (“USPTO”) as a Thomas Edison 
Fellow. So obviously my comments here are not in my capacity as a fellow at 
the USPTO, but I am planning on doing research related to the Patent Trial and 
Appeal Board (“PTAB”) over there. Finally, my wife is in the pharmaceutical 
industry, so I get a little bit of a sense of where the patent issues are in that 
[arena] as well. 
I have been really fortunate to be able to look at patent policy and intellectual 
property rules in a lot of different settings, and I am fortunate to be at 
Georgetown, which is building the leading law and technology center and hiring 
some of the best people in the world on these topics. But today, I want to talk 
about something that is central to my research, and that is the role of data in 
patent policy analysis. So, when we talk about patents and innovation, regardless 
of your political stripes, there are a lot of common goals I think we all share. We 
all want to promote innovation, right? This is important for growth; we think 
that is important. All else being equal, we also want to increase access and 
affordability of technologies for consumers. We want more people to get access 
to technologies that are created because that is the whole goal. 
But how do we get there? There are a lot of questions that have an empirical 
foundation but not so much [the] kind of facts as to what is actually going on. 
So, some questions might be: Do longer patent terms actually incentivize more 
innovation, or do they just create what we call dead weight loss1 or monopoly 
cost?2 Which industries care the most about patent protection? We have ideas as 
to who we think cares about patents, namely pharmaceuticals and biotech 
companies, but is our conventional wisdom accurate? Is there a way of actually 
testing this? What do consumers and the general public, think about patents? Do 
we have any sense of what it means to them when you show them that a product 
                                                          
 1 Deadweight Loss, INVESTOPEDIA, https://www.investopedia.com/terms/d/ 
deadweightloss.asp (last updated Sept. 24, 2019) (explaining that deadweight cost is “a cost 
to society created by market inefficiency, which occurs when supply and demand are out of 
equilibrium”). 
 2 See How Is Profit Maximized in a Monopolistic Market, INVESTOPEDIA, 
https://www.investopedia.com/ask/answers/041315/how-profit-maximized-monopolistic-
market.asp (last updated Apr. 2, 2019) (explaining how a monopolist controls the market 
through control of the price and quantity demanded). 
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is patented? How much does venue matter in patent litigation? So you litigators 
out there will appreciate that one, and it is a fraught issue. Does it matter where 
a lawsuit is filed, in terms of its outcome, when we are talking about patent 
litigation? And do patents contribute to rising drug costs and cause pharma 
companies to produce what we call “me-too drugs”?3 
In different papers, I have touched on each of these different questions. [But] 
obviously we have a limited amount of time here, so I am just going to talk about 
a couple of my research papers that I have been working on to give you a flavor 
of how data can play an important role in designing optimal patent policy. 
To begin, which industries care most about patent-term? This is a paper that 
is forthcoming in the American Law and Economics Review and as I said, our 
conventional wisdom is that patents matter the most in pharma and biotech. But 
is this necessarily true? How can we test this? In this paper, I take advantage of 
what we call in economics, a “natural experiment” approach.4 Most of you are 
probably familiar with the Agreement on Trade-Related Aspects of Intellectual 
Property Rights (“TRIPS”), right? And what did it do? It changed patent term 
rules in the United States. Before TRIPS, you had a fixed seventeen-year term 
as of the date of patent issuance; after TRIPS, you had a potential twenty-year 
term, marked from the date of patent filing. So, I am going to take advantage of 
this change in rules to try and get at in which industries patents actually matter 
the most. 
So, to lay this out for those of you who might not be familiar, patent 
prosecution is a back and forth process where you apply for a patent at the U.S. 
Patent and Trademark Office. Then the USPTO issues a response to you and as 
a patent applicant you file your response to them and then you go back and forth 
and eventually, the patent might issue. So, in this example, let us just say it took 
four years for the patent to issue. Under the old rules, how much patent term 
would you have? You would have a seventeen-year term from the date the patent 
issued. Under the new rules, what is your term going to be if you took four years 
to prosecute the patent? Well, now the twenty years is counted from the date you 
filed your application. So your effective patent duration is only sixteen years. 
Now, why does this matter? Under the new rules, you have an incentive to 
speed up your patent prosecution, and there are ways in which you can actually 
                                                          
 3 See Yaniv Heled et al., Why Healthcare Companies Should Be(come) Benefit 
Corporations, 60 B.C. L. REV. 74, 84 (2019) (describing “me-too drugs” as involving “an 
increasing number of pharmaceutical companies pursu[ing research and development] 
projects aimed at developing therapies for ‘lucrative’ medical conditions, many of which are 
not considered severe or which already have effective therapies available”). 
 4 Malcolm B. Coate & Jeffrey H. Fischer, Why Can’t We All Just Get Along? 
Structural Modelling and Natural Experiments in Merger Analysis, 8 EUR. COMPETITION J. 
41, 46 (2012) (comparing natural experiments in economics, where policies are observed 
over a period of time, to controlled experiments, where the conditions are set). 
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speed up your patent prosecution by being quicker in your responses to the 
Patent Office. And so, what might we predict? We might predict that in 
industries in which patent term is particularly important, you are going to speed 
up patent prosecution more than in industries in which patent term is less 
important. 
So, the question is, who sped up the most in response to TRIPS? First of all, 
the usual suspects, such as drugs, genetics, organic compounds, certainly did, 
but they were not the only ones. It turns out, that [other areas, including] 
communications, computer hardware and software, electronic business methods 
and software, and semi-conductor devices, all sped up [in patent prosecution] in 
response to TRIPS. 
So, what does this mean? It is not conclusive, but it is at least one data point 
that suggests areas that we think may not care so much about patent protection 
might be more sensitive than we think. Maybe patent duration matters more for 
software patents than we thought. Maybe, we used to think, well, software is 
going to be obsolete in seventeen to twenty years so we should not care. Maybe 
that is true, maybe it is not, but these areas did seem to respond to TRIPS in a 
way that was kind of surprising, whereas mechanical patentees did not respond 
much, so not everyone sped up. So, patent term might matter more to computer 
software patentees than we previously thought, and we are able to use data to try 
and look at that and challenge what the conventional wisdom actually might be. 
I should follow up, there is another paper that I am writing on this that takes 
advantage of the fact that this rule was retroactive, and we tie this to stock market 
events study data to look at the companies that benefited the most from the 
retroactive application of this rule. We look at what happens to their stock 
market prices and then we are able to use that to back out the dollar value of an 
additional year of patent protection. That is a work still in progress. 
The second paper I am going to talk about [involves] what we call a field 
experiment. So, there is this big, basic question: Do consumers actually care 
about patents? When you see a product and it says patented on it, and you are a 
consumer, are you more likely to buy the product than if it did not say anything 
at all? So when I ask this question to patent attorneys, I say, how many of you 
think [this fact] makes people more likely to buy the product? About half the 
people raise their hands, the other half do not. So, it is not clear. 
But are consumers more likely to buy a product when they find out it is 
patented? You might say, “Well, Neel, all you [have] to do is compare the sales 
of patented and comparable unpatented products and see which one sells more 
and you will have your answer.” Well, the problem is, you cannot really make 
apples-to-apples comparisons like that very often. A patented product is 
different from an unpatented one. So, I cannot just look at raw sales data to make 
2020] The State of Innovation in the Union 9 
that kind of analysis. 
So, what do I do? I run an experiment. I go to a retail pharmacy chain that has 
agreed to let me do this, and I make more salient the patent status of all the 
patented goods there. So essentially you go in and you put a big “patented” label 
on the front of the product. Since I have multiple stores, what I do is in one store 
I use a patented label that says, “this product is patented.” In the other store, I do 
not put that patented label and so [I utilize] what we call in economics a 
difference in differences technique.5 I can compare how the sales change in the 
treated store versus the control store over time, and that gets me the estimate of 
what happens when we make patent status more salient. In other words, once I 
sort of hit the consumer on the head with the fact that this product is patented, 
how does it affect their purchasing behavior? We can actually get at a causal 
impact through this mechanism. 
Now, obviously, I cannot ask all the consumers in the store what they are 
thinking when they decide to purchase or not purchase a product. [The] only 
thing I can do is look at the retail scanner data after the fact. So how can we get 
at more detail with respect to what the consumers are actually thinking? Well, I 
also run this as an online, randomized experiment. [I show consumers pictures 
of products with] the only difference being whether a patented label is present 
or not. [Some] products actually say they are patented on the front, but [others] 
do not. When you do this treatment, people do notice it and they report that the 
product with the patented label is more innovative. 
So, when you compare the responses of the people who received the treated, 
patented label, versus the people who did not, the people who received the 
patented label do respond and say it is more innovative. They do say the product 
is better made. However, they are not more likely to buy [the product]. They will 
say, “Yeah, yeah, it is more innovative, it is better made, but I am actually not 
more likely to purchase it.” 
Now, you might think, this is an online experiment, so I am not actually asking 
them to spend their dollars, right? So, a person’s reported preference in the 
survey might be different than his or her actual purchasing; in economics we call 
this revealed preference. This is where the store experiment comes in. I could 
use the retail scanner data to look [at the following]: When I make the patent 
status more salient, what happens to sales? It turns out, at least so far, that the 
retail scanner data confirms the last result. In other words, once you make patent 
                                                          
 5 Difference-in-Difference Estimation, COLUM. U., https://www.mailman.columbia.edu/ 
research/population-health-methods/difference-difference-estimation (last visited May 29, 
2020) (explaining the difference-in-difference technique as “a quasi-experimental design … 
used to estimate the effect of a specific intervention or treatment … by comparing the 
changes in outcomes over time between a population that is enrolled in a program (the 
intervention group) and a population that is not (the control group)”). 
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status more salient, people are not more likely to purchase the product. That 
might not be true for all products (maybe you need larger sample sizes) but at 
least this starts the conversation as to what consumers actually care about. 
I should also mention, I did some background research on what people 
actually know about the patent system as part of the online survey, and I was 
actually heartened to see that people knew more than I thought. For example, in 
my survey of about 2,800 folks, about 83 percent knew [about how one obtains 
a patent; they knew that one obtains a patent] by getting approval from a 
government agency. In addition, 31 percent recognized [a patent] as a 
government-granted monopoly, and 21 percent recognized it as, “Okay, a 
product is using a new technology.” When ask[ed], what must one show to get 
a patent, the most common answer was [that] the product is different from 
existing products. [While] this is not a perfect answer, it is surprisingly good. 
So, people do seem to understand what patents are, which is another result. In 
conclusion, people believe patented products are more innovative, but that does 
not necessarily make them more likely to buy a patented product. 
I can now briefly talk about a couple of other research projects, [including 
one that asks,] how much does patent venue matter to litigants? You litigators 
out there will remember that there is a case called TC Heartland that came out 
in 2017 that changed patent venue rules.6 Essentially, it greatly restricted where 
patentees can file patent infringement suits.7 They used to file them all in the 
Eastern District of Texas, and now, a lot of these cases are shifting to the District 
of Delaware, where a lot of companies are incorporated. So, what we do is we 
run a stock market events study, which means you look at the stock market price 
of companies before and after the TC Heartland decision and see how the market 
responded to the decision as a way of kind of measuring how investors feel about 
it. Who is optimistic about this decision? If your stock market price goes up, it 
suggests you are really optimistic about this decision. So, whose stock went up? 
If you are a Delaware-based company who previously was really likely to be 
sued by non-practicing patent entities, some folks refer to them as patent-trolls, 
you were optimistic; your stock market price went up a lot. So, this is a paper 
that, with Ofer Eldar over at Duke, we published in the Cornell Law Review. 
Another paper asks, how can we reform patent law to encourage meaningful 
pharmaceutical innovation and lower health care costs? I do not have time to get 
into the details of this because obviously it is a complicated area, but one of our 
ideas is to try and encourage something we call value-based patenting. In the 
healthcare sphere, there is this whole thing about value-based pricing. We talk 
about this notion of value-based patenting. So, the idea here is, maybe we should 
                                                          
 6 TC Heartland L.L.C. v. Kraft Foods Grp. Brands L.L.C., 137 S. Ct. 1514 (2017). 
 7 Id. at 1519–20. 
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have patent protection that is variable, that is dependent on the emerging value 
of the technology in the medical and drug device area. And so, we can actually 
go much farther than we could in the past because electronic medical records 
allow us to more accurately measure the value of new technologies as they 
emerge. [T]his is a paper in the Minnesota Law Review with my colleague Gregg 
Bloche. 
So, the bottom line is, data is something that not only can help us answer 
existing policy questions, but [it can] tell us what questions we should ask in the 
first place. Every time you answer and say, “Consumers seem to care about 
patents, [or] consumers do not seem to care about patents [when it comes to] 
their purchasing behavior but they say it is more innovative,” that produces 
another question [of] “well why is that the case?” [So data] sets the stage for 
thinking about other questions we may not have even thought of looking at 
before. It provides a neutral way to test whether the conventional wisdom is 
correct, which relates to the TRIPS paper that I talked to you about [in which] 
we just assumed patents are important in some sectors and not others. This is a 
way of actually testing to see whether that is true. And the exciting thing is this 
is an unprecedented opportunity that we have today, to use data in patent policy. 
We have higher quality data than ever before, and we [also] have better empirical 
techniques and computational analysis than ever before. So, I hope that my 
research and the research of others in this field really pushes things forward and 
increases the use of data in patent policy. Thank you. 
[Applause.] 
EVERARDO RUIZ: [So far] we [have] talked about kind of the description 
of what is happening, you know, where the research is; then there is what is the 
government doing? There is obviously a lot of pro-innovation [type] policy. In 
the second portion here, boots on the ground, the U.S. government promoting 
innovation, I wanted to bring up Paul Zielinski, Director of the Technology 
Partnerships Office at NIST. [When] we think of NIST, we maybe think of 
something else, but [NIST is] involved with voting standards and technologies 
surrounding democracy [and] cybersecurity. [NIST can answer questions like,] 
what is being funded? What is working? So, let us go ahead and listen to that. 
Paul? 
PAUL R. ZIELINSKI: Thank you. I really appreciate the opportunity to come 
and speak with you today. This is something that is very near and dear to my 
heart. I actually have the privilege and honor of doing two different kinds of 
things in my position over at NIST. Not only do we do a lot of research as a 
federal laboratory in various areas of standards and [into] some really high tech, 
interesting things, [but, in my role,] I [also] get to transfer those things out of the 
laboratory and to the marketplace directly. 
The other thing we [do comes as a result of being] part of the U.S. Department 
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of Commerce. As part of the Department of Commerce, we actually have a lead 
role in coordinating this activity across all federal agencies, for the government. 
So, I want to talk mostly about that topic today and I think it is really relevant to 
this group, especially since we spend a lot of money on federal research 
throughout the United States every year. [It is] roughly in the neighborhood of 
about $150 billion a year, so that is a lot of money that we are putting out there. 
But I always make the point, and I know this group is not really surprised by it, 
that we do not make anything. We do not manufacture, we do not distribute, you 
cannot buy consumer goods from the government; it is just not our role. So, 
intellectual property really serves as that key bridge that allows us to get things 
out of our laboratories and into the marketplace. If you look at the Department 
of Defense, they are not out there manufacturing these things, they are buying 
them. All this technology needs to find its way into the marketplace and that 
requires a lot of money. So, I talk about $150 billion, but there is a lot more 
money on the private side. That is really where the intellectual property rights 
come in as a way to protect that investment and those dollars that are going to 
be put in from the private side and are going to support the development and the 
transfer of that technology to the marketplace. 
So, this is a really high priority for the administration. President Trump even 
put in his President’s Management Agenda what we call a cross-agency priority 
goal. [Therefore,] this is one of the highest priorities of his administration in 
terms of how we are going to manage things. So we have a part called lab to 
market, we have multiple agencies involved in this whole thing, we have a 
number of different workgroups over at the National Science and Technology 
Council (“NSTC”), [and] we have a group that supports that. Again, the whole 
concept is getting inventions and ideas out into the marketplace and getting the 
funding for those on the private side [in order] to create new products and 
services. So not a great big surprise. Well, one of the interesting things about 
this cross-agency priority goal is this is one of those few things that actually 
crossed over administrations. And so, although it is in President Trump’s 
Management Agenda, you would also find this in President Obama’s 
Management Agenda, which I think is one of those rare things that is really 
heartening to see. [It is heartening] that this is such a priority for the federal 
government. Again, it is because we spend so much money on doing research 
and how do you benefit the people in the United States from that research 
investment. 
So, let us talk a little bit about how we are doing in these types of things. We 
just talked a bit about data, so let me share with you a little bit of 
data. Unfortunately, the best data we have is actually from 2016. In fact, my 
office actually produces the primary data sets on federal inventions that you get 
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out there. [There are] a couple of big points that you can see looking at the trends 
overall once you normalize everything. [For example,] we do great in doing 
partnerships; our cooperative research and development agreements are 
CRADAs. So, we work with other parties, and one of the most important parts 
of these agreements is actually the transfer of intellectual property rights. Some 
of the other primary things that you get out of these [agreements] are the abilities 
to work together, to create knowledge, and to create ideas and put them out there 
in the marketplace. So, you get an advantage out of working with the folks that 
we have in our laboratories. 
The disappointing part [of all this] is that our invention disclosure is a bit 
down. Fortunately, licensing activity is up, but again, sort of the bottom line to 
all of this is that we are pretty much flat on funding. So, it is not a great big 
surprise, but if you are not funding new things, you are probably not seeing much 
return on that. But we are doing a better job at licensing those inventions out, 
and again, that is the most critical thing that we can do because nobody is getting 
the benefit of these inventions if they just sit there. So, just looking intramural, 
the $150 billion [I mentioned before] is what we spend on all research and 
development. We will get [the money] roughly in thirds: about a third goes to 
universities, about a third goes to industry, and about a third of that is within our 
federal laboratories themselves. So, [we are] looking at roughly a third, only a 
mere fifty billion [dollars] or so. 
So, where are we doing patents? Where are we seeing actual inventions 
coming out from our laboratories? Of course, you get the big other category, but 
it is pretty well distributed; we do a lot of different work. [When it comes to] 
sensors and measurement, of course, I am happy to see from NIST that 
measurement is such an important thing. [But] how we are doing sensors, 
[including] how we are actually picking up these things in the environment and 
how we are understanding our systems, that is incredibly important. Really, there 
is a pretty wide distribution of where these patents are coming from in terms of 
industrial sectors. To put a number to it, we pursue roughly 2,500 patents a year 
in our federal laboratories, which is not a huge number, per se, versus a lot of 
industries. The flip side of that is we only patent things where we really need to 
use [a patent] to raise capital, and we transfer it to the private sector for them to 
raise money. So that is where we are with what we are investing in. It is also a 
pretty good snapshot of how you would work with a federal laboratory and 
where you might find some of this information. 
Now, we have many databases out there with different pieces of 
information. For example, if you want to find information about what we are 
doing under the President’s Management Agenda, you can go to a website called 
performance.gov. Specific information on patents that are available across 
agencies comes from our Federal Laboratory Consortium, and we actually have 
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another lovely website, federallabs.org, and you can find information there. 
So, one of the things that we have done recently at NIST is put together what 
we call our green paper. What is a green paper? It is really just some ideas; it is 
a discussion paper. What we did is we went out last May and we asked: What 
can we do better in terms of supporting innovation within our federal programs? 
This includes the entire $150 billion; how do we better transfer this to the private 
sector? How do we increase what we call return on investment? This does not 
necessarily mean dollars to the government, that is not the return we are looking 
at here. But, how do we get a better return in terms of jobs, increases in economic 
performance, all of these lovely other things, for taxpayer investment in research 
and development? That is the return that we are talking about here. And so, what 
we did is we went out, we did our request for information, and we got many, 
many responses; [the number of responses] was really quite voluminous. But we 
came up with this paper and we have roughly fifteen findings in different areas 
and the idea behind it is how do we increase innovation? So, I welcome you to 
look at this at nist.gov/tpo/roi. We really do not propose any changes to the 
bedrock Bayh-Dole Act through this, but there are regulatory changes that are 
envisioned here. Some of the questions that we discuss in this green paper 
include: How do you fund university research? Also, when you get to the end of 
the program, and you say, “Well, I have this great idea, but I do not have enough 
money to get a patent on this,” how do you address that? We also talk about 
topics like software, how do we work with copyright versus patent, and how do 
you really do intellectual property protection? So, there are a number of great 
ideas in this [green paper] that we are trying to develop. And of course, the 
reason we call it a green paper is because it is simply a discussion piece that is 
meant to get people talking; it is meant to move things along. It is really not the 
document that makes the changes themselves. All of that will be coming and we 
do intend to move on this within the coming year. Now I will go all the way back 
to what I was talking about on the President’s Management Agenda. That is 
really where we are executing these [ideas and changes] at this point. They all 
fit into the milestones and the agenda that we are working on across the 
government. With that, I will conclude and turn it back over. 
[Applause.] 
EVERARDO RUIZ: So that was one perspective. But it is interesting; it is 
funny. I can think of the Rockefeller [era] back when a billion [dollars] was a 
billion [dollars], you know, we are talking about huge sums of money. But using 
it efficiently is obviously what everybody wants. So, thank you [Paul]. 
It is with pleasure that I now invite G. Nagesh Rao from the SBA up to the 
platform. If you recognize the name, you may have read it in Financial Times or 
TechCrunch. He has been around on a lot of different platforms, but he has also 
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been involved with growth accelerators and Patents for Humanity, [working 
with] a really wide, diverse set of uses for intellectual property. So, I thought it 
would be perfect for him to come here and talk about innovation kind of as he 
sees it from the SBA. 
G. NAGESH RAO: Thank you [Everardo] and thank you everyone. Again, it 
is nice to be in the same room with my friend Jeff Langer. I have known him for 
about fifteen to twenty years now, both of us are alumni of Rensselaer 
Polytechnic Institute (“RPI”). So, thank you all for having me here today. I also 
see some former colleagues of mine, [including] Paul [who has been] wonderful 
as always. He and I used to work on the Technology Transfer Lab-to-Market 
efforts [together]. So, I am looking at this from a couple of different lenses. I 
used to work on the Small Business Innovation Research (“SBIR”) program,8 
but I do not work on that anymore. I now engage in information technology 
(“IT”) modernization efforts for the agency because of the great job I did on 
sbir.gov. I asked Paul to help me out here with this because I think what is really 
important is understanding the different resources that are out there when it 
comes to innovation, intellectual property, and scaling up for startups and small 
business companies. You know it is funny, we have already talked about patents 
and that is the elephant in the room, but it is not just patents, it is trademarks and 
it is copyrights; it is the notion that intellectual property is an asset. The property 
right is an asset, an asset that you can leverage. 
So, I worked for seven years at the Patent Office, then I went to the private 
sector for a while, and then the SBA reached out to me and said, “Hey, come on 
back and help us out with venture capital private equity” because I was doing a 
decent job out in the private sector. I was actually doing patent curation at that 
time out in Silicon Valley for a number of high-tech startups, some of which you 
may have heard of. What was really fascinating was talking to the people there. 
They would ask, “Why do I care about patents?” But, half the time, they were 
conflating the terms patents, trademarks, copyrights, and they did not even 
understand the value proposition. 
When you look at the valuation of any startup or small business, the 
accounting equation is that assets must always equal the liabilities plus 
shareholder equity. That is a standard accounting equation. So, when you look 
at that value proposition, you need to understand that intellectual property is a 
valuable asset. It is an asset class that rises in value over time. And I think what 
has been critical here is that when we look at high tech research and development 
(“R&D”) perspectives, that asset of intellectual property actually has a really 
                                                          
 8 About SBIR, SBIR, https://www.sbir.gov/about/about-sbir (last visited May 29, 2020) 
(explaining that the SBIR program is the Small Business Innovation Research program that 
helps small businesses to “explore their technological potential and provides the incentive to 
profit from its commercialization”). 
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strong return on investment down the road. I mean, the investments that we have 
made since the 1970s have really materialized to this day when it comes to R&D. 
That is why what the question comes down to is how much of that furthering of 
R&D, those investments, [can be attributed to] the private sector? [Is it 
attributable to] the private sector plus the public sector? What does this really 
look like? I know when I worked on the SBIR program, there were some 
economic studies done. In terms of data, the National Aeronautics and Space 
Administration (“NASA”) SBIR program produced a four to one dollar return 
on investment for every dollar that NASA SBIR contributed. For the Air Force, 
it was a fourteen to one dollar return on investment. For the Navy, it was a 
nineteen to one dollar return on investment. 
Half the technologies we see in our lives today had some sort of 
federal R&D funding to it, whether it was SBIR or something affiliated with it. 
In fact, 80 percent of the components of [the cell phone], this device that we are 
addicted to, were [the result of] R&D funding from the federal government SBIR 
program. Actually, 100 percent [of these components] are [a result of] R&D 
funding from the federal government when you think about it. Ultra-Scan 
Corporation came up with the biometric touch, Photobit did the CMOS pixel, 
which was Eric Fossum’s work, and Qualcomm did the microprocessor. So, 
there is an important role that the government plays in de-risking technology 
development and spurring innovation forward. I know you all know that, but I 
think it is a fascinating thing when you look at it from the SBIR lens. Still, I 
think it goes beyond that, and Paul, if you do not mind, please step up for a 
second and talk with me about this. [Describe what it is like] when you look at 
it from phase zero to phase three and examine all those different bridges that are 
helping with the commercialization valley of death. 
PAUL R. ZIELINSKI: One of the things I get to do for NIST is probably run 
the smallest SBIR program in existence. It is pretty exciting to do because we 
do basic research in a lot of our laboratories. If you look at universities, they do 
a lot of basic research. The question really becomes where do you get the money 
to cross this valley of death? The research institutions typically are not able to 
bring things to the level of maturity and de-risking that a company needs in order 
to get into the marketplace. I just went through the whole thing about, “well, we 
rely on private capital,” of course, that is the reason why we have intellectual 
property; when we want some investment, we need to get money from the 
private side [since] we cannot fund everything from the government side with 
what we have available. However, we can actually try to spur innovation with 
something like an SBIR program and that is really the key. In fact, I know [the 
program’s] tagline is “America’s Seed Fund.” So, the idea is, this is our 
investment in small business and how we try to use that SBIR program to 
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basically kickstart some of these small businesses so they can grow up and 
become bigger businesses and, oftentimes, have an exit event. But that is great 
because that puts products into the hands of people, and that is really the goal of 
all of this; [the goal] is not just to develop things, it is to make a difference in 
people’s lives. 
G. NAGESH RAO: Agreed, and I think what is critical is that when you look 
at innovation in America there is this à la carte approach. Large companies play 
their role and small companies also play their role. I mean, Steve Sasson, who is 
a good friend of mine, he would say, back when he invented the digital camera 
for Kodak in the 1970s, “If I had known the SBIR [program] was around, I may 
have thought about that. I might have said, all right, I will leave Kodak and I 
will go start my own small business company.” Now what is interesting is the 
fact that there is an opportunity like this, especially since many countries do not 
have this opportunity. [Here,] we are reinvesting in our society; we are 
reinvesting in our talent pool. You know, intellectual property is the result of a 
heterogeneous society. It is the result of a diverse society, a very culturally mixed 
one. I think that is what is so interesting about Silicon Valley. [Out there] I see 
this cadre of intellectual minds from a multidisciplinary perspective. That is 
what moves the engine; that is the fuel that drives the economic engine forward. 
So, what you look at is what are the catalyst points? What are the little nuggets 
that come in, molecularize around, and then go up? I think you are looking at 
these different catalysts and federal funding, R&D funding, is the government’s 
way of outsourcing R&D needs. Really all we are doing is catalyzing that 
movement and really the private sector moves it forward down the road for that 
mass scale, long-term commercialization, but you need to have someone to make 
that first bet. And it is a non-dilutive and you get to keep the intellectual 
property; that is a steal at $2.5 billion per year. That is my quick observation to 
you all. The last thing I was going to say, [focuses on how] different technology 
is progressing. So, it took sixty-eight years for the airline industry to hit fifty 
million users and Pokémon GO just a couple of weeks; that is crazy. But that is 
also the sign of disruptive innovation and I think that is a dialogue we need to 
be having with ourselves; as you allow for this faster timeline to happen with 
disruptive innovation, how do we come to equilibrium with it? 
[Applause.] 
EVERARDO RUIZ: A good observation. Those are like shock waves at the 
end. They are not slow and steady waves. So, those were a couple of perspectives 
and we are talking about huge figures of fifty billion, or even a couple of billion 
[dollars]. Interestingly enough, you can say it is a Silicon Valley thing, but it is 
not like innovation does not happen worldwide, and it transitions everywhere in 
the world. I keep thinking about moving around Saudi Arabia and seeing people 
with iPhones with fifty thousand patents tied up in this phone when it comes to 
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digital rights management (“DRM”), memory control, software, and the 
processor. And yet, there it is, and it is more than we went to the moon on. It is 
incredible and worth protecting. 
Next, let us pivot to [the concept of being] in the trenches. I alluded to asking 
people that are fighting the fight in the trenches, what is happening, what is 
working, what is not. So, let us pivot over to that view from the trenches. PJ 
Bellomo, Executive Chairman of Blue Sources, will start the discussion. Also, 
one thing I have noticed with all of these [presentations], is that it is no longer 
just one technology, it is all very interdisciplinary. So, we look forward to 
hearing [PJ’s] discussion. 
PJ BELLOMO: I am PJ Bellomo, Executive Chairman of Blue Sources. Our 
patented water security technology detects toxic chemicals in water by 
combining artificial intelligence with a 24/7 real-time data feed from the world’s 
most advanced water quality sensors: live fish. So, here is the story. A few years 
ago, United States public water utility, Tuesday afternoon, all quiet on the 
western front, pH is fine, dissolved oxygen is fine, conductivity and all the other 
typical physical water measurements [are fine]. What you want in a water utility 
is you want the operators absolutely bored out of their minds because everything 
is working fine. First-generation Blue Sources device alarms, the fish, say, 
“Something is wrong with the water.” Therefore, something must be wrong with 
the Blue Sources device because everything else is fine. So, we go through a 
routine where we switch out the fish; it is a normal routine that happens every 
couple of weeks. We put in new fish, and they alarm as well. Well that is a little 
unusual, [since we used] two different sets of fish. The operators then take a 
water sample and it comes back from the lab. [They say,] we have a problem, 
this water is filled with diesel fuel. We do some investigation, and, keeping some 
things confidential, I will just say there is a barge out on the source waters with 
a massive problem: a leak from the diesel fuel tank is going into the water, and 
that water is going into the intake at this public water utility. Fish saved the day 
because none of that [water] went to the public. 
Now let me tell you a little bit about a technology transfer story. The United 
States Army is worried about a problem. It is worried about accidents and 
negligence, but it is more worried about sabotage. So, problem number one that 
the Army is worried about is it is going to have troops deployed somewhere, 
maybe even at a base in the United States, and instead of some of the enemy 
putting explosives inside of a vehicle and trying to go through the front gate and 
do nefarious things, [the Army is worried that] the enemy might just poison the 
water supply. This is a problem that Blue Sources is working on [solving]. 
There is also a different problem, and this [problem] is not as obvious. While 
there are many places in Southeast Asia where they have water problems, there 
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is a place in particular where they had water problems and they spent the last 
fifteen to twenty years fixing those water problems. Therefore, today the answer 
for [accessing] drinking water [in this area] should be to open up your tap 
because on average you are going to have better water than if you got your water 
out of a city in the United States, which actually has very good drinking water. 
But that is not the answer, and [the people there] still use bottled water, which 
makes them spend a lot of money they do not need to spend. This then also 
creates a recycling issue with all the plastic. So those are problems that we can 
solve. To help do so, we have this patented device we can use. We actually 
access this [and similar] patents through a tech transfer program through the 
United States Army, and we have a cooperative research and development 
agreement [in place]. 
As far as how it all works, the secret is twofold. [First there are] the patents 
around the entire system. To take away the mystery, I will tell you that, and as 
it turns out researchers have known this for a while, when a fish is breathing, it 
gives off a localized electric field. Moreover, Mother Nature has been working 
on these fish for ten million years, so if you put bad things in their water, they 
breathe differently, and when they breathe differently, those electric fields 
change. In our device, we have eight fish and we are monitoring those electric 
fields, and [the fish] essentially vote with their breathing. We then send those 
signals, as well as physical signals about the water, into a neural network and 
the neural network determines whether or not there is a problem. So, that is what 
is going on. We are actually in the valley of death that [was just referenced]; we 
are actually trying to make our way through the valley of death. We have a 
market ready product, and we are trying to win some customers before we go 
out for funding and target markets, government facilities, drinking water, and 
then wastewater. [In fact,] the first-generation device is actually serving all of 
these markets. 
Now I am moving really quickly but what I will tell you is I have been asked 
to talk about this state of innovation. Well, I am just a guy who is out there 
running startups, so I have a limited perspective and it stems from my personal 
experience. So, I thought I would explain my resume so that when you 
understand my perspective, there are these inherent limitations. I had a 
traditional career, and I was another RPI geek by the way. I worked as an 
engineer for many years, and then I was sort of a corporate suit doing consulting 
for Fortune 500 companies. Then, one of my clients hired me and I did e-
commerce and supply chain work. Finally, in 2002, I found my home in the 
startup world. So, I will discuss the state of innovation but let me [first] take 
these last seventeen years and comment a bit. I have been an executive for six 
startups, I am currently the executive chair at Blue Sources, I have been the chief 
executive officer for [several] software startups, and I have also been the chief 
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operating officer at a startup. When you are at a startup, you look for exits, and 
I have only had one [exit], since [one of the startups] had the good fortune of 
being acquired for $45 million by a public company. I have also invested [in 
startups] myself; I have taken my hard-earned money and I have invested in four 
startups. 
There was also a period in that seventeen years during which I worked with 
the partner of a software design firm. So, I did the design work on two other 
pieces of startup software. I have also personally been in two different pitch 
competitions. Since 2010 I have been a member of Mindshare. I think about 
twenty years ago, the guys from AOL started this not-for-profit called Mindshare 
to help the next generation of entrepreneurs prepare to run companies, and at 
this point, I think Mindshare has brought 850 CEOs such as myself through the 
Mindshare program. And so, I am part of this 800-person CEO network. I have 
served on the board of directors at a startup accelerator. I have served on the 
board of advisors at techfrederick. I recently had the good fortune to be able to 
mentor at the New York Business Plan Competition a group of college students 
pitching startup ideas. I have been an occasional entrepreneurial guest lecturer 
and I was a finalist for a professorship, an endowed chair professorship in 
entrepreneurialism. I did not get that, but [this shows] that I also have an interest 
in the academic area. So, it is with all of that that I offer my perspective on the 
state of innovation. 
Quite simply, my experience has [shown me] that intellectual property law 
has worked; it has worked in the world that I have lived in. However, there was 
one problem that I encountered while running a company and it had to do with 
what I refer to as a patent troll. But the Supreme Court handled that [issue] in a 
case that happened about five years ago. That case actually made the patent troll 
disappear.9 [On another note,] one thing that does not get discussed is the call to 
refrain from changing bankruptcy law. There are places that cannot take the risks 
that we can take. I have never had to take a company through bankruptcy, but 
anybody who has invested widely in startups probably has done that. 
[Bankruptcy] does not come back on the individuals and that is the bedrock that 
allows the culture here to continue to work, and I think that works really well. 
Somehow, in the United States, at least in the world I live in, if you try hard and 
you fail, it is okay, and that cultural view is really important. I do not brag about 
my failures, I do not wear my failures, but I have certainly had some, and I think 
this [acceptance approach] works really well. So, those are all real pluses to the 
state of innovation, and while there are still some things that we can improve on, 
my read is that [the state of innovation] is alive, well, and thriving. Frankly, I 
                                                          
 9 Octane Fitness, L.L.C. v. ICON Health & Fitness, Inc., 572 U.S. 545 (2014). 
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wish I was pursuing my engineering degree now because I am finally at home 
in the startup world, and back then it did not seem as accessible. 
So, where do I think we can improve? Intellectual property protection costs 
are still very expensive. At Blue Sources, I have taken over a family of patents, 
and [these patents] have helped us get where we are today. But, just the 
maintenance costs on those patents [are substantial.] Now, I do not know how 
to fix that issue, and lawyers need to get paid, but maybe a startup will figure 
out how to lower [intellectual property protection costs]. That is one area I think 
we can improve in. For my last two problems, I do not know how to fix them, 
but I am not bashful about drawing attention to them. With the growth of 
entrepreneurialism around the United States, there are all these posers that are 
surfacing. I will not call out the specific schools, but I had the good fortune to 
be a finalist for an endowed chair [professorship] and there are all of these 
professor of entrepreneurship [positions] around the United States; it is like this 
new thing. And let me tell you, not only am I not qualified to apply, but, if Steve 
Jobs was still around, he would not be qualified. Elon Musk, Bill Gates, they are 
not qualified. They do not satisfy the job requirements for most professor of 
entrepreneurship [positions]. You need a PhD, you need years of teaching 
experience, and you need to be widely published to be able to teach students to 
be entrepreneurs. 
[Applause.] 
PJ BELLOMO: I mean, it is absolutely ridiculous; I do not know what else to 
say. The last thing I will say has to do with a very delicate topic. I believe the 
way we handle healthcare costs, but more specifically health insurance, is 
actually something that gets in the way of innovation in the United States. Now 
that sounds like a leap, [and you may be asking,] “What is the connection?” 
Well, I will tell you. I do not know about anyone at Kodak, but I have friends 
that were at Qualcomm, IBM, Apple, and Microsoft who have done well. [They 
are] engineers, maybe managers now, and product design people, [and they 
worked in these roles for] fifteen to twenty years. My 401(k), it is in good shape; 
I have made good money and I am ready to take a chance. But you know what? 
I have a four-year-old with juvenile diabetes and I just cannot [take that chance]. 
I am standing in front of you today as a man whose grandmother and grandfather 
died of cancer, father died of cancer, mother survived cancer, older sister 
survived cancer, cousin died of cancer, and who survived cancer. Making the 
decision to go into a startup world that might lead to failure and could leave me 
without a job in six months and with no healthcare insurance is absolutely 
terrifying. There are geniuses all around America ready to come out and help the 
innovative world, and they are stuck in jobs because they cannot take the risk of 
going out and someday finding themselves without health insurance. I have no 
idea how to solve that problem, but I have never heard anybody speak about it. 
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So, given that I had a microphone for ten minutes, I thought I would raise [the 
issue]. Now, let me end the way my partners always like me to end: You want 
safe, clean water? Trust the fish. 
[Applause.] 
EVERARDO RUIZ: Passion. I like it. Again, interdisciplinary. I mean at first 
I thought, “Fish? What?” That is because I am coming from the semi-conductor 
world and disciplines like telecommunications and electronics measurement. I 
thought, “You have to be kidding me.” But then I realized that [PJ offered] a 
good approach. Interesting. 
By the way, as a side note, I remember looking at a deal in Poland, and that 
the laboratory that first figured out how to make silicon wafers had to pass. Why? 
Well, what does the bankruptcy law look like? They had not even tried [using] 
it. It had not been exercised. So, I am sort of in violent agreement with the point 
there. 
We are now going to move to pumps. From Zoeller Pump, we are going to 
have Matthew Byers come up, who is the corporate intellectual property 
manager [at the company]. You know, there is a tendency when you think of 
pumps to think of water and oil and think it is this crusty, old business. But, 
despite [pumps] being mechanical, there are all kinds of electronics, software, 
and DSP involved, especially in a market that is a global market, and that is what 
we are going to hear about. So, take it away, Matthew. 
MATTHEW BYERS: I met Jeffery Langer last summer at the USPTO 
Intellectual Property Chinese Roadshow where I was giving a talk, and we 
became friends. Then, during the past year, he asked me if I would continue that 
presentation here with you all. 
So, I am going to talk about pumps. You may have heard of our company. 
Many people have basements and many people have sump pumps. We have 
succeeded over the course of eighty years in producing what we think—and I 
think that there is plenty of evidence to support this—is the best sump pump in 
America. We can claim that because we are also the most copied sump pump in 
America. Our design for our core product is actually utilized by many 
competitive products. 
Our main location is in Louisville, Kentucky. We have been doing this for 
eighty years and we consider ourselves a legacy brand. We also own a company 
in northern Indiana called Flint & Walling. Back in the day, they built windmills. 
So, when you look on the prairie and see those windmills, they were [made by] 
Flint & Walling. That company has been in business for 150 years. So, I figure 
they are like a legacy times two. We have about 950 employees and we do about 
$200 million per year in sales. We have an international presence. We are family 
and employee owned. We are community conscious and innovation minded. 
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So, we are talking about how pumps can be sexy and whatever. Well, we 
pump water. We pump sewage. We grind sewage up. We move it around. Pumps 
can be fractional horsepower, or they can be very big. They can be one hundred 
horsepower or larger. It is the engineering community that figures out what is 
needed. And then we build these things that are needed to move the water. They 
involve controls. They involve collection systems. There are environmental 
concerns. 
Anyway, so you have Zoeller Pump and Flint & Walling linking industries. 
We have our own plastic injection molding company. Years ago, most of those 
went away. We have one in Indiana and it is a very interesting process. We own 
large submersible pumps. Wolf Pump is down in Texas, and so are these large 
submersible irrigation pumps. We have a Controls Division up in Canada. We 
have a pump company in Taiwan. We have an environmental business in China 
which is now serving as a place for us to distribute our pump products, and I 
spend a lot of time working on the China project. I made about forty-nine trips 
in and out of China, since this [business] is brick and mortar. 
At Zoeller, innovation involves basically four areas. We have products, new 
products, product improvements, and manufacturing process. We build things 
and we do not want to share our processes, some of which are very old, but some 
of which are very new, with the outside world. So, we think about that, [when it 
comes to] sales and marketing processes and then business processes. I am now 
going to hit a few highlights of each of these. 
So, on the new product side, we had a conversation last night. We were talking 
about idea capture and what people do. What we do, [is] we keep people out of 
our R&D areas. If you come to our company, you cannot tour there, and that is 
just the way it is. I work with our engineers. I work with the people that are our 
technicians, the people that are working on technical things all day, every day. 
In our business, that is where innovation comes from, those people. One day, I 
am out in the field and I get invited to go to a distributor’s place. By the way, I 
am a technical guy; my area is decentralized wastewater. So, I can treat 
wastewater without giant sewer systems. Anyway, I go to this conference and it 
is a bunch of plumbers. They are in this distribution house up in Wisconsin. It is 
fantastic. It is wintertime. It is cheese curds. It is beer. It is local people sharing 
from their hearts exactly what their troubles are in their profession. It was 
wonderful. It was a great harvest. I bring that information back to the company 
[and] that shapes our next generation of basin systems. 
For example, you go out in the world, and you deal with actual practitioners. 
They will share with you and they will teach you things if you are smart enough 
to listen. Anyway, our people at our place, I encourage them to record their 
thoughts in “idea books.” I have gone around to all our divisions. I have 
distributed these books. They do not instantly write their ideas down. This is 
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something you have to say over and over and over. One of the things we teach 
these days is that communication does not really happen until the other side gets 
it. Well, do not expect them to get it the first time. So, you hammer away. 
We had a board of directors meeting the other day and our manager from the 
Taiwan facility came over, and he was thrilled to share with me their first idea. 
Now, they have had a bunch of ideas, but this is the one that is recorded in the 
“idea book.” It is really good. It is innovative. It is something that we will file a 
provisional patent application for in the United States, probably in the next ten 
days. It is a really great idea and it came from a bunch of young guys that were 
working together. It is a multi-disciplinary effort, but it is really, really 
something. 
Anyway, it was great to see that. Many ideas instantly going into “idea books” 
might be ideas that people are routinely working on. But maybe after a little 
while, maybe annually, or every six months even, you have a group of skilled 
people come and look at the “idea book,” people that are really good in your 
business, and they can separate the wheat from the chaff. They then select the 
ideas that we want to move forward. Certain ideas are going to be very exciting 
to us because we can make money. We want to make money. We want to earn a 
profit. All those 950 people that work with us, they have families, and everybody 
needs to get paid. And so, we get excited when we see something that we think 
we can commercialize. We want to avoid that area where we have this great idea, 
but we cannot do anything with it. 
So, we have “idea books,” we patent things, and we are teaching the folks in 
our business about diligence and what you have to do when you have an idea. 
Many people that have ideas, their ideas are born in a vacuum. They do not 
actually understand that there is another person on the planet that likely has the 
same idea, and then if they run into that, they get discouraged. Well, do not get 
discouraged. Move up one notch. You can do that. That is what we do with our 
people. If they have a good idea and they hit a roadblock, we tell them let us just 
take it to the next level. We ask, “what would be the next cool thing?” We 
encourage them to not let things die. Anyway, diligence is very important, and 
not just in the patent area. But if we build any product for sale, we have to do 
the diligence so we know we can sell it. 
Working with outsiders on products, that is huge. Work with consultants. But 
to hire a consultant you need the proper paperwork. You need to make sure that 
people do not reveal what you are doing. And then if you pay somebody, some 
technical person to do work for you, you need to make sure, contractually, that 
the work is owned by you, because if you have not done that right, you are going 
to have a problem. Also, when you have people in your organization working on 
innovation and going above and beyond, you create a reward structure. So that 
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is a little bit about products. 
[I will now move on to] manufacturing processes. In our factory, we have 
proprietary information [and] we have trade secrets. I have gone around to our 
various divisions and tried to help the managers understand that which can be 
shared and that which should not be shared. We do tours. We have factory tours. 
That is a big deal to us. Historically, we would show everybody everything. 
These days, my message is do not do that. In fact, I go to the people that want to 
show people things and I ask them, “What do you really want to show?” If a 
product is made in the USA, that is something we are proud of. You want to 
show that? Show that. Every one of our pump products is tested repeatedly. You 
want to show that? Okay, show that. [People may say] “I want to show quality. 
I want to show that we have this super high-level of quality.” Well, do you 
necessarily need to take the tourists into the quality laboratory and show them 
the instrumentation? 
One day I took the tour and I am standing next to a man from Indonesia. He 
is a brilliant engineer and he is asking really great questions. Surprisingly, the 
employees are answering them. They answered everything that he asked, and I 
was shocked. If it was me, [I would not have allowed this to happen], and in fact, 
in our company these days I have been accused of being anti-tour. Well, I just 
wear that mantle now; I am anti-tour and I am the no-fun guy. I am the guy that 
demanded that we revise all our labeling for California’s Proposition 65. That 
was unpopular. But anyway, that is a different topic. 
[Laughter.] 
There is also manufacturing, and I did want to cite one example. We have a 
machine. We have a computer numerical control (“CNC”) machining center in 
Louisville.10 When you buy a machine, the people are going to tell you the 
maximum that machine can put out given the parts you want to build. Well, what 
if you bring one hundred years of experience and direct it at that machining 
center? And all of a sudden, you start figuring out how to gang tool this thing 
and do some amazing things. Then the next thing you know, that machine is 
producing 125 percent of what the manufacturers said it would. As far as I am 
concerned, that is innovative. That is the sort of thing I do not necessarily want 
to teach the world. I do not know that I do not want to teach the world that, but 
I also do not know that I do. We have that type of thing going on all the time. 
Now to marketing. I highlighted marketing videos. That was a big deal for us 
recently. Our marketing people want to show everybody everything. Our 
marketing people contract with outsiders to build, say, videos. If you do that, in 
                                                          
 10 What Is CNC Machining? An Overview of the CNC Machining Process, ASTRO 
MACHINE WORKS INC. (May 22, 2017), https://astromachineworks.com/what-is-cnc-
machining/ (defining CNC machining as a “manufacturing process in which pre-
programmed computer software dictates the movement of factory tools and machinery”). 
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the file folder for that project, you will have written on paper, evidence of 
licensing if there is music involved. Music is a big deal these days, and 
companies our size are just learning about all this, but proper licensing is huge. 
Copyrights. In our business, we copyright many works. If it is original to us, 
we are going to copyright it. If our marketing people create a clever advertising 
campaign, you will see some copyright language associated with that, but our 
work may still be infringed. If there is infringement, we may not act, but at least 
we have a legal leg to stand on. Within marketing, these people come up with 
very creative works all the time. So, it is important for us to teach these people 
how to protect those works as best they can. 
We also have a couple of trademarks. This is in the area of marketing as well. 
One of these trademarks has to do with the color of our Model 53 pump. The 
other has to do with the image of that pump. Remember I said that the pump has 
been copied? Well, the good news is that pump has been in the marketplace since 
about 1982 and it possesses something called “acquired distinctiveness.”11 So, 
we were able to convince the USPTO to issue these trademarks, and we have 
successfully used these trademarks against several knockoffs. It is really great 
to have that ability. 
Finally, there are business processes. In your business offices, you might have 
people using software. You might buy, if you are a manufacturer, enterprise 
resource planning software and work with people that are coming in, consulting, 
and providing you a code. But maybe that code is not exactly right for you, and 
you make a number of changes and adaptations. You need to think about that. 
Those adaptations could become desirable to the people that provided you that 
language. Also, all of that could be copyrighted, and you need to think about that 
on the front end. You also need to realize that if you are playing with these 
things, you may create something that is novel and that somebody else wants. 
This is an important consideration. 
At Zoeller, within the business office, you have different kinds of innovations 
happening such as with the IT code. In manufacturing, when it comes to our 
processes, we are not doing brain surgery, we are not out there on the cutting 
edge, but we have people working on very up-to-date manufacturing processes 
that are interesting to us and outsiders. We have products in development, 
products under improvement, and patents. We also filed various provisional 
[licenses] this year, and as those things become dated, we will follow-up. With 
                                                          
 11 Acquired Distinctiveness (Trademark) Law and Legal Definition, USLEGAL, 
https://definitions.uslegal.com/a/acquired-distinctiveness-trademark/ (last visited May 29, 
2020) (explaining that a mark acquires distinctiveness when, as a result of extensive 
advertising and widespread use, the mark becomes capable of serving as a trademark by 
associating the mind with a particular source of goods and services). 
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that, I will conclude my portion. 
[Applause.] 
EVERARDO RUIZ: Thank you. I have this specialized bicycle and on the 
seatpost it says, “Innovate or Die.” So, if you are competing successfully, the 
modesty was appreciated, but you are world-class. You have to be, or you are 
dead. Well done. 
So, we have talked about [the view] from the trenches. Who knew about fish? 
Who would have thought? We also talked about pumping. Again, everybody 
thinks it is some crusty, old industry. But we saw it is not at all. 
We recently had an internal discussion with the Patent Office about artificial 
intelligence (“AI”). We think about AI and how it is applied to a lot of things 
and not just used in isolation. It is employed in healthcare, astronomy, and a 
number of other fields. That is why our final speaker, Meghan, is here. She co-
founded and now leads the company VEDA Data Solutions. So, let us go ahead 
and invite Meghan here to speak. 
MEGHAN GAFFNEY BUCK: My name is Meghan Gaffney Buck. I am one 
of the two founders of VEDA Data Solutions. We are a data processing company 
in the healthcare space. We work primarily with Medicare and Medicaid plans. 
I wanted to talk a little bit about the state of innovation as it applies to AI, 
machine learning, and some of the newer technologies from both an intellectual 
property perspective and a general-competitiveness perspective. 
Just to kind of set the stage for healthcare, the reason why we are so excited 
about the opportunity to innovate in this space is because of the crushing cost 
that folks in these parts like to discuss ways to solve. One out of every three 
healthcare dollars is spent on administrative overhead. So, when we talk about 
healthcare dollars, we are talking about your premiums. One out of every three 
dollars does not leave enough money in the system to adequately care for 
patients in the way that we need them to be cared for from the beginning of life 
all the way through the end of life. In addition to that, health plans alone are 
spending $10 billion inefficiently due to data inaccuracy. Data inaccuracy 
includes everything from having to manually hand key-in information because 
it has come in through a fax or a PDF that cannot be properly ingested into a 
data system, to improperly entered claims. Then on top of that, there is the fraud, 
waste, and abuse that exists in the system that cannot really be attacked, because 
today, within our healthcare environment, whether it is Medicare or Medicaid or 
private payers, they cannot even tell you accurately where physicians work and 
see patients across the country. That is where VEDA starts to attack the problem. 
But we come at it from a unique perspective. 
So, I come from a political background. I spent a dozen years in Washington, 
D.C. working with appropriators in the House of Representatives and Senate on 
the political side of the aisle, and healthcare costs were something that were a 
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constant topic of conversation. I had the chance about three and a half years ago 
to work with my co-founder, Bob Lindner. He is an astrophysicist and he was 
out of postdoc at the University of Wisconsin. 
He built an AI system that is now used in forty research facilities across the 
world, including NASA, to process radio telescope data in an automated way. 
Now, what was unique here is that scientists that are coming out of the hard 
sciences, particularly in astrophysics, biology, and chemistry, are used to seeing 
data in the real world. What that means is that it is messy. It is full of holes. It is 
messed up by every iPhone and Hot Pocket being microwaved on planet earth, 
and you cannot get any more of it. That data looks a lot like the data that you see 
in the healthcare system, data coming in on electronic health records 
(“EHRs”).12 If there is something that is miscoded, you cannot go back and say, 
“Dr. Smith, three days ago, you saw this patient. Did you really mean to code it 
that way?” So, data cleansing and dealing with imperfect data sets is something 
that is intrinsically valuable in healthcare. 
When we initially started to tackle this problem, we focused on provider 
directories, which seem very simple but [they] are actually plaguing the industry 
by creating a lot of manual costs associated with not understanding where 
physicians are practicing and what kind of patients facilities are treating on a 
daily basis. But we did not have all the answers. Bob came from academia, and 
I was not ready to give up when we hit brick walls. So, what we found was that 
there were innovative techniques around data cleansing, processing, and 
imputation that were being developed in academic institutions across the country 
not within computer science programs, but within other disciplines that are not 
necessarily thought of as the places for AI and machine learning innovation. 
We partnered with Dr. Lars Hernquist at Harvard. He founded the Harvard-
Smithsonian Center for Astrophysics, and he works on the largest 
supercomputers in the world, modeling galaxy formation from the Big Bang 
forward. He also works on a budget that would be considered less than a 
shoestring in the capitol. So, they have had to innovate ways to process data 
quickly, accurately, and in a cost-efficient way. He helped us learn and look at 
research that was happening in the academic space and bring that innovation into 
industries so that we could deliver our products at a price point where customers 
would be successful. 
We also partnered with other scientists. Dr. Sara Walker came out of the 
Beyond Center, and she also teaches at the Santa Fe Institute. She is a complex 
                                                          
 12 What Is an Electronic Health Record (EHR)?, HEALTHIT.GOV (Sept. 10, 2019), 
https://www.healthit.gov/faq/what-electronic-health-record-ehr (defining “Electronic Health 
Record” as a digital version of a patient’s paper chart that provides a “real-time patient-
centered record that makes information available instantly”). 
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systems physicist. She has dealt with the healthcare system personally but had 
no idea that her work could be applied to some of the problems we were facing. 
[Her work focused on] tracking institutional change within systems and how one 
organic change might affect other places within a living system. We applied 
those technologies to changes within the healthcare system to model when 
regulation might impact data. For example, when tax reform passed, there was 
a huge change of providers moving from C corporations to pass-through 
organizations to take advantage of tax reform. That created a data nightmare in 
claims systems across the insurance industry. We could project the most likely 
changes that would happen so that we could deliver better results for our 
customers, and it was based on work that had nothing to do with either computer 
science or healthcare. 
So, we continue this investment in basic research, and it was a radical choice 
as a startup going to our early investors and saying, “We want to have an internal 
lab that funds some basic research and partners with our scientific advisors, but 
we do not want it to have to be tied to healthcare. We do not want it to have to 
be tied to the projects that we are doing. What we want to do is train scientists.” 
So, we see this investment in basic research both at our corporate level and in 
the country, generally, from a government level as a training ground for the 
future innovators, whether they are entrepreneurs or engineers that are building 
this technology. We have been successful. We are currently bringing on a 
Fulbright scholar over the summer that is coming to be a part of our lab. We also 
have one to two-year fellowships where we bring people in partnership with our 
academic institutions in to do research, expose our internal scientists to that type 
of rigor, and then send them back to the academic sector where they can create 
technologies and do research in their fields of origin. Or, we can even inspire 
them to enter industry. 
One of the reasons why we really need them to enter industry is this $3 billion 
paragraph. There is a piece of a regulatory guideline that came down in 2015 
requiring insurance plans to do manual outreach to doctors and hospitals to ask 
them questions about who works there, what kind of patients they see, and about 
the insurance they take. It is an extraordinarily expensive way to curate data. It 
is also not at all effective. By every measure, including measures that come out 
annually from the Centers for Medicare & Medicaid Services (“CMS”), this 
methodology only produces about 50 percent data accuracy on healthcare 
providers across the country. It does not work. It is wildly expensive. But it is 
also stifling innovation. Because of this paragraph, in one legislative notification 
that came out from CMS in 2015, companies have been forced to create solutions 
that are manual. 
We bucked the trend and took a chance. We were lucky that we had investors 
that were willing to back us going against this legislation because we were 
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asking our customers to invest in automated technology that increases their data 
accuracy from 50 percent to 95 percent in the course of a week. But they had to 
do it while still spending money on manual outreach that is ineffective and 
wasteful. And so, one of the challenges for innovators entering regulated 
industries are policies like these that are regulating and mandating methods 
rather than the outcomes that we are trying to achieve. So, one of the things that 
I wanted to bring to everyone here, whether it is from an intellectual property 
perspective or a policy perspective, is that pace of change that Jeffery talked 
about in the beginning, and the pace of adoption will continue to increase. But 
if we have policy and regulation that requires outdated methodology, we are 
going to stifle U.S. innovation while innovators move to other parts of the globe 
that do not have those similar regulations around methodology and that focus 
more on outcomes. 
I have three recommendations that I will leave you with. In order, from an AI 
perspective, to enhance U.S. innovation to incentivize cost-savings, but also to 
create the kind of commercialization from regulated industries that can make the 
economy grow, focusing on results and not methodology is critically important. 
Removing the regulatory hurdles that we talked about and incentivizing cost-
savings [is crucial]. From an intellectual property perspective, there is one thing 
that I would add after listening to everyone here today. So, I know a question 
that I am going to get around AI and intellectual properties will focus on 
algorithmic protections. Well, 80–90 percent of what we do is more traditional 
than that. There are systems that we set up, data processing, data cleansing, some 
hardware components, the way we architect our cloud architecture, all of that is 
very protectable. I do not think we have to have a race to change the intellectual 
property infrastructure to meet AI where it is today. However, I think looking at 
growing the industry as a whole is a good first place to start, because so much 
of what we already do is protectable. The things that are holding us back are 
workforce and regulation. So, if we can lift those barriers, I do not think we are 
going to have an intellectual property problem, I think we are going to have 
flourishing industries here in the U.S. Thank you. 
[Applause.] 
EVERARDO RUIZ: Nice. We had a saying at MIT, “Tell me how I am 
measured, and I will tell you how I will behave.” So, that was interesting 
commentary on something that at first seems like, “Oh it is simple. There is only 
one paragraph of policy [I need to follow].” Well, $3 billion for 50 percent? I 
can flip a coin for free, right? Well done. We now have ten minutes left for 
various questions. So, I will kick it off before everyone else jumps in. 
Everyone has some protectable technology, some of which is just held secrets, 
some of which is patented, it really depends on the industry we are talking about 
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here. There is more and more software and ideas and now, in theory, with the 
internet, it is able to just disappear instantly. Can you talk about trade secrets 
and what advice you would give other innovators for going forward? How do 
you protect trade secrets given that they are just so amorphous? 
MATTHEW BYERS: In our business, it is not really amorphous. What I am 
teaching the different divisions in our company, is that the managers need to 
look around at the processes that they are engaged in, and they will decide what 
they do not want to share with the outside world. They just make a business 
decision. Then, since it is a trade secret, it must be maintained as a secret. If you 
do not maintain it as a secret, it is not a secret and it is not actionable. So again, 
in the manufacturing environment, you put up barriers, you put up signs. You 
just do these things that are practical, but it is a business decision in our world. 
MEGHAN GAFFNEY BUCK: I would say, in our perspective, it is more 
about looking at what qualifies as protectable and what might not [qualify as 
protectable]. It is an investment decision of how we want to spend our dollars. I 
listen to my lawyers when they weigh what is likely to be protectable against 
what we should keep as a trade secret. 
PAUL R. ZIELINSKI: From the federal side of things, we are not really able 
to keep per se a trade secret. I mean proprietary information we can protect, and 
in fact, in that green paper we talk about the ability to maybe extend the period 
of time during which we can protect that information in order for it to reach the 
intended market. But, in the long run, we want to make things available, so trade 
secrets are not really our area. 
G. NAGESH RAO: From my days in the private sector, the rule of thumb I 
would always use with the engineers and our intellectual property counsel was 
if piece of technology could be reverse engineered, then go for the patent. But, 
if it can really be kept a secret, then keep the trade secret. There is a benefit to 
open innovation and there is a benefit to closed innovation. So [our goal was] to 
just understand what particular piece of technology we were working with so as 
to determine the right property right for it. 
PJ BELLOMO: So likewise, a patent would be an exception to the rule: 
seventeen years, mostly software, keep it a trade secret. The reality is, for us 
startup folks, the hardest thing actually is not the engineering. In my experience, 
the hardest thing is sales and marketing and scaling the business. So, you could 
spend all your time trying to get a patent, and in the meantime, someone beats 
you to market. So, it is an exception. 
PROFESSOR NEEL SUKHATME: I will speak from the perspective of my 
startup. We have five issued patents. So obviously, as a patent attorney, I 
recognize the importance of that. But I also recognize that patent law changes 
over time. What might be patentable now may not be patentable in the future. 
You have to diversify your risk, and so, we have been careful to make sure that 
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we have core technologies protected by patent law but also core components that 
are essential to making our business work, protected by a trade secret. So, I think 
there is a notion of diversifying that is important and having both patents and 
trade secrets is a way of dealing with that. 
EVERARDO RUIZ: So we have Neel Sukhatme here from Georgetown, PJ 
Bellomo from Blue Sources, Paul Zielinski at NIST, G. Nagesh Rao over at the 
SBA, Matthew Byers from Zoeller Pump, and Meghan Gaffney Buck from 
VEDA Data Solutions. Please feel free to ask questions. 
MISSIONARY RANGE: Thank you. Hello, I am Missionary Range and I am 
the intellectual property owner of “Black Lives Matter,” “All Lives Matter,” and 
“Blue Lives Matter”; all of that is my work and it was a sermon. So, I am asking 
this question, but it is not based upon my intellectual property. My question 
focuses on Blue Sources and Flint. How is Flint using your technology and have 
there been improvements in the water in Flint, Michigan? 
PJ BELLOMO: Thank you for the question. They are not, but in their defense, 
I will say that the U.S. Army put the technology out years ago. It was the first-
generation technology used in a limited range and our second-generation 
technology has only been available for sixty days. So, we are new to the market 
and no one knows about us. We are trying to land the first few customers and 
then expand either to Flint or any place else. 
But first-generation technology is in use in other cities around the United 
States. As a security technology, it is interesting, [because] people typically do 
not like to tell you what they are using as a defensive mechanism. So, the cities 
that are using this technology, most of them are not advertising that they are 
using it. It is almost like cybersecurity; you do not tell the bad guys what you 
are doing to protect your IT assets. 
MISSIONARY RANGE: Is it lawful for the water not to be clean in Flint? 
PJ BELLOMO: I do not know enough about the Flint situation to speak in 
any type of detail. But, I would love to talk to them if they want to talk to us. 
EVERARDO RUIZ: Other questions? 
DR. CARL J. SCHRAMM: This is for Paul. I read the green paper from cover 
to cover. I have just one question: Has there ever been an honest to goodness 
study of the Innovation Corps (“I-Corps”)13 and its effectiveness? 
PAUL R. ZIELINSKI: I am not aware of one. I know we have questions about 
that ourselves and we have been talking a good bit. I talked about the different 
                                                          
 13 NSF Innovation Corps (I-Corps), NAT’L SCI. FOUND., https://www.nsf.gov/news/ 
special_reports/i-corps/ (last visited May 29, 2020) (explaining that the National Science 
Foundation Innovation Corps (I-Corps) exists to prepare “scientists and engineers to extend 
their focus beyond the university laboratory” to accelerate NSF-funded research projects to 
commercialization). 
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workgroups and some of the ideas behind putting together some level of 
evaluation. I mean the biggest thing that I see reported right now is how many 
teams have gone through the system? However, the real question is, how many 
of those teams have been effective? But I do not have any data like that. 
DR. CARL J. SCHRAMM: Even the premise seems confused. I have heard 
[I-Corps] advertised several times as focused on getting people in the middle of 
their careers with PhDs or PhDs and MDs and taking the career scientist out of 
the laboratory, and apparently America will be better off if we teach them how 
to become entrepreneurs. 
PAUL R. ZIELINSKI: Well, its original start is actually tied back to SBIR. 
So, the original start of I-Corps actually came out of a funding program for 
National Science Foundation (“NSF”), SBIR recipients in order to improve their 
level of success in reaching the marketplace. That is actually where it came from 
and what its origins in terms of funding by the NSF were. Now, it has changed 
a bit since then and there have been many teams. 
G. NAGESH RAO: Yeah, so, there has not been an honest to goodness 
assessment on the I-Corps program yet. That is correct. But I think what is also 
interesting is that it has only been a few years. I-Corps is still in its nascent 
stages. 
DR. CARL J. SCHRAMM: Well, actually, the green paper says it has been in 
place for almost a decade. 
G. NAGESH RAO: Well, it depends. From an NSF perspective, yes. But 
remember, it is an à la carte approach. Every agency that has adopted some I-
Corps-like program has approached it a bit differently, and I think that is one 
thing to keep in mind. Since it came out of the SBIR program and then a number 
of agencies were adopting it, there are a number of different mission needs to 
consider. So, like the SBIR program, there is an à la carte approach. You have 
granting agencies like the Department of Energy, National Science Foundation, 
Health and Human Services where the technology commercialization pathway 
to success is just to get the technology out to the market; that is their mission at 
the end of the day. They just want it out there for the good of the public. Whereas 
with agencies like the Department of Defense and NASA, they do not operate 
on a granting perspective for the SBIR; it is contracting. The reason why is 
because at the end of the day, Defense and NASA, they are looking to acquire 
that technology; it is an acquisition perspective. And so, it also creates a 
delineation with the small businesses. Do you wish to be a high-tech small 
business company? Maybe the contracting vehicle is the way to go. Do you wish 
to be a startup that actually scales up and grows? Maybe the granting [vehicle is 
more appropriate]. There is that delineation. Not every startup is going to be a 
small business, not every small business is going to be a startup. But having 
that à la carte, diverse approach and enabling that across the American economy 
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has proven to be pretty successful so far. Now, it is going to be interesting as we 
become more globalized economically and with the other countries’ approaches 
to this effort. But the one way I think the U.S. has stayed on top from that 
perspective is by maintaining its non-dilutive stature and not taking equity. I see 
Singapore doing it, I see Taiwan doing it. I advised Sri Lanka and Vietnam on 
that perspective when I was an Eisenhower Fellow back in 2016. They both took 
my option, chose not to take an equity stake, and allowed the free market to play 
because, at the end of the day, the free market is democratic in nature. 
EVERARDO RUIZ: I wish we had more time. We could go on for hours on 
these topics and as we can see it is all very nuanced. Let us thank the speakers 
for what we have established with respect to what is currently happening and 
then we will talk about the next five years with the next panel of speakers. 
[Applause.] 
AMI PATEL SHAH: Good afternoon everyone. We are going to get started 
with our afternoon panel. It is about the next five years and where we are going. 
For those of you that are here to learn about case law, 101, PTAB, you are at the 
wrong meeting. This is more about thinking at a macro-level about where our 
country is going and where it needs to go; it is not looking at the micro-level. I 
would like to focus our question and answer portion, our agenda, and where we 
want to go at the macro-level so that our country moves forward in the next five 
years and, hopefully, the people on this panel and those in the audience will then 
work at the micro-level to get us there. I hope to have a very fruitful dialogue 
amongst us. 
The second panel is going to involve questions, comments, and disagreements 
on how we are going to move forward. I want to get started with how digital 
innovation is giving rise to new business models. However, as the previous panel 
has explained, regulations are not keeping up quickly enough with the 
technological changes that we are seeing in the industry. So, what we want to 
focus on in the next few hours is: what are policymakers and regulators to do, 
and how will we get there to ensure that our country moves forward in the next 
five years and keeps its lead in innovation? 
I want to start with a Forbes article that recently talked about the new digital 
era, the post-digital era that talks about the new technologies that are coming to 
the forefront, including blockchain, AI, augmented reality, virtual reality, 
quantum computing and on and on. There are plenty of technologies. What are 
we doing based on patent law? How is patent law keeping up with this post-
digital era? If you really deep dive and look at what those four technologies are, 
they are pretty much software, data, and computer-driven. So, what are we doing 
to keep up with that in the law and what are the companies doing? I want to start 
out with Patrick Kilbride. What is the Chamber of Commerce doing and what 
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does it see from an American standpoint? 
PATRICK KILBRIDE: Thank you. It is great to be here and congratulations 
to IIPCC for the initiative. This is always a great conference every year. As we 
look at where our economy is heading, my division at the U.S. Chamber of 
Commerce is focused on intellectual property and innovation. I think the core 
work that we have done in the intellectual property area on patents, copyrights, 
trademarks, and trade secrets is really going to come to be seen as the tip of the 
iceberg in a twenty-first century knowledge economy. We are going to be much 
more focused in the future on other intellectual assets, know-how, information, 
and data. We are going to need to do a much better job of bringing the same 
discipline that we have brought to conventional intellectual property rights and 
applying that in creative ways, where necessary, to a much broader range of 
intellectual assets. 
It starts by discreetly identifying those assets. By being able to account for 
them and finding ways to appropriately define ownership rights around them and 
how to enforce those rights. Then we need to create the markets for the know-
how, the information, the data, the relationships that encompass that broader 
understanding of intellectual capital. This is going to be necessary because we 
have seen [a change] in the last thirty years. In 1986, 86 percent of all corporate 
assets were physical, plant equipment type assets. Today, it is exactly the 
opposite; 86 percent of corporate value is now invested in intellectual capital. 
But we still do not know how to take care of that, and in most of the world, they 
have not even got the basics right, such as patent and copyright protection. So, 
if we think of conventional intellectual property as addition and subtraction, we 
need to be ready for calculus. 
AMI PATEL SHAH: Thank you. As a follow-up, on the previous panel a 
gentleman from NIST talked about how most of the current innovation that we 
have is government-funded, as well as intellectual property protection and what 
the government led to. But some of the data he pointed to showed that it is even 
keel, or it is even negative, and innovation is going down, and that government 
funding has stayed flat. So, to Professor Schramm, what does that mean in terms 
of economic competitiveness, and what are we going to do about that? I know 
you had asked a question previously. 
DR. CARL J. SCHRAMM: My question was focused on if we had any 
objective understanding of the I-Corps program or if it was doing anything. I 
mean, the government seems to bring that out of the rigging like deus ex machina 
that will solve problems, that will, in that case of the NIST green paper, make 
federal employees more entrepreneurial, which is something to contemplate. I 
often joke that the last time we had entrepreneurial accounting it was Enron that 
turned out. Anyway, the point I get to is this: a long time ago, in the George W. 
Bush administration, I chaired the panel that measured entrepreneurship in the 
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United States in the twenty-first century to see how we were doing 
comparatively. We could not get to a finalized answer because we cannot even 
measure entrepreneurship in the United States, and you saw in the [previous] 
presentation that it is all surrogate measures. But what we could get to is that the 
hardest measure is headed downward. So, to get to where I think your question 
leads, [we should ask] what can we do about this? I now see this from two 
perspectives: one [perspective stems] from the research we did at Kauffman 
around innovation and entrepreneurship, and the other is a professor’s 
perspective. And I think, in an odd way, we have made too much of intellectual 
property, at least in the eyes of proto-entrepreneurs. They are all thinking 
constantly about the idea, and the protection of the idea to the point where the 
quality of the idea is often lost. I will end my remarks by saying that one of the 
most tragic things I have experienced in my new professional career as a 
professor involved a student describing a great idea. He thought it was a great 
idea, but when he ended his presentation to me he said, “Do you think the 
government will let me do this?” 
AMI PATEL SHAH: I will now move to Andrei Iancu. Will the government 
allow us to do this in the post-digital [era]? 
DIRECTOR ANDREI IANCU: Obviously, the government does not stop 
people from doing something in that context. It would just protect them from 
others doing the same thing for a period of time. To address the NIST green 
paper, that effort is obviously focused on government-sponsored research and 
how to transfer that government-sponsored research either from government 
labs or university settings, where government has funded at least part of the 
research, into the private enterprise. Government-sponsored research in the 
United States is approximately half of all of the R&D in the United States. The 
other half, more or less, is provided by private enterprise. Historically, one of 
the greatest advantages this country has had is private enterprise and the fact that 
we have a free market system backed by a strong intellectual property system 
that can create independent, privately funded R&D. Think about Bell Labs as a 
very good example of that and many other institutions like it. 
Unfortunately, I do think that over the past few decades, privately funded 
research has not increased at the rate that it should. Again, we have seen in the 
past few decades the demise of major research and development private 
institutions, less investment in private R&D by certain large entities, and less 
focus by small inventors to do their own [R&D]. That is problematic because, 
frankly, we cannot compete with China, for example, at the state level, and we 
do not want to compete with them at the state level with respect to investment 
in R&D. We want to do the best we can, but really, our forte is in the private 
side, and as the panel goes on, we can explore how we can incentivize more and 
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more private research. I do believe that strong intellectual property protections 
and reliable, predictable intellectual property systems are critically necessary 
ingredients to incentivizing private R&D. When your student comes to you, it is 
not a question of whether the government will let him do it. It is a question of 
whether the government will protect what he has done, since, without that 
protection, it is less likely that the student will focus his energy and effort on 
developing that project as opposed to some other project, or that he can attract 
investors to invest in the project. We want to make sure that we do what we can 
to incentivize private developments as much as possible. 
AMI PATEL SHAH: I have a follow-up question, but [Mr. Ragan] I want to 
ask you, what is Teva Pharmaceuticals doing in the pharm and bio industries? 
Also, where do you see it going in this post-digital era? 
COLMAN RAGAN: I guess where Teva would come in is that we are one of 
the private engines of R&D. We are a pharmaceutical company, so the R&D that 
we do is mostly funded by ourselves, by the sale of our products turned back 
into R&D. The amount of R&D in the biopharmaceutical space that comes from 
government funding probably is less. There is still some, but that is the smaller 
engine. You have the source coming from startups that companies will acquire 
and then they will take the next leap and there will be further innovation to 
deliver the product to the market. So, where we come from, what we are seeing 
right now in terms of innovation is less innovation at the startup stage. There are 
fewer assets for us to go and bring into our company to take to the finish line. 
So, that means that we are going to need more organic R&D and to spend our 
own money to grow the next products, the next therapies for patients. In our 
space, that is kind of what we are seeing; that is where we are in the cycle now. 
AMI PATEL SHAH: I want to follow up. Director you talked about having 
predictability and reliability in intellectual property to have a great eco-startup 
system. You know, we have seen a lot of changes in the last five years and I do 
not know if as an investor in patents, where I believe patents are a property right, 
that they are an asset per se but that reliability and predictability has completely 
vanished. I just do not know if the asset that I invested in four years ago is still 
an asset four years later. If you see where the indications in markets are going 
or the new innovations, you see that it is reflected there. You have made great 
strides, Director, coming up with the Section 101 rules and changes, but yet the 
agencies that are implementing those rules are not implementing them, or, in the 
ChargePoint case,14 completely disregarding them. And so, how does that work 
if they are going to disregard these changes? My big concern in this post-digital 
world is all the new technologies are going ahead, and people are not patenting 
them and therefore, they are not available. And I do want to get to the next 
                                                          
 14 ChargePoint, Inc. v. SemaConnect, Inc., 920 F.3d 759 (Fed. Cir. 2019). 
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section about when people decide to keep things as trade secrets as opposed to 
keeping them open so that we can grow on the technologies that they have 
patented. Most new technologies are software-based, yet software is not 
patentable or there is a perception that this is not allowable. 
DIRECTOR ANDREI IANCU: Very good point. I will save some of that, 
especially in the second part of your question, for the next section and my 
discussion of the huge benefits of having a patent system as opposed to keeping 
things as trade secrets. In terms of reliability and predictability of intellectual 
property rights, it is absolutely necessary. Like any other instrument, you want 
them to be reliable. You want the dollar bill to be reliable. You want the financial 
systems in the United States to be reliable. Likewise, you want the intellectual 
property instruments to be reliable. And, obviously, as you have indicated, we 
have lost some of that in the past number of years, and we are trying to bring a 
measure of that back. 
As it happens in the United States, we have a divided government. We have 
three independent branches, and that has significant advantages. However, a 
result of that is that the judiciary is fully independent. Again, on balance, I think 
that is a very good thing, but they do not have to follow our guidance. The Article 
III courts can look at what we do at the Patent Office, and they can agree with 
it, disagree with it, or ignore it completely. We will see what they do with the 
recent guidance we issued on Section 101. The fact of the matter is, it is fairly 
new right now. We, at least so far, have not seen the courts commenting on them 
directly, one way or the other, in any meaningful way, and at the same time, I 
have not seen any change in approach in their recent cases that have come down. 
You mentioned the ChargePoint case.15 There have also been a number of other 
cases. The Athena case,16 for example, on the bio side. They are on the same 
path, and they have been for a few years, and we will see what they do. I will 
say this though: I think our guidance that we issued in January of this year is 
working extremely well at the USPTO. Our examiners understand it, they get it, 
and it makes a lot of sense to them. It really has lifted a huge burden off of their 
shoulders. It does not solve the problem completely, but it certainly makes the 
analysis much more straightforward for them, much more consistent and 
predictable. That is a very, very good thing. 
I will also say this: the status quo prior to our guidance is simply not tenable. 
I cannot imagine a world where we would have to go back at the USPTO to the 
situation we had prior to our guidance. It is simply no longer a tenable situation. 
We have 8,500 examiners; we see hundreds of thousands of patent applications 
                                                          
 15 Id. 
 16 Athena Diagnostics, Inc. v. Mayo Collaborative Servs., L.L.C., 927 F.3d 1333 (Fed. 
Cir. 2019). 
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a year and probably over a million office actions a year. Decisions have to be 
made all the time, and the way Section 101 was before our guidance, there were 
no standards, and there was no particular framework to follow. It was not a 
predictable approach by our examiners in light of the case law or for our 
applicants. I think we have solved that, and I think the framework we have is a 
very good one. Hopefully, we can keep doing it. If the courts do not adjust, and 
again I see no evidence that they are on a path of adjustment, the only thing left 
is for Congress to step in, and I do know that there is a current effort to address 
that situation. But I am quite hopeful that we have finally turned the corner on 
Section 101. 
COLMAN RAGAN: To follow up on the Director’s remarks, first of all, 
thank you for trying to clarify the [Section] 101 issue at the Patent Office. I 
would agree that the courts are confused and maybe that Congress is going to 
consider what to do with what is or is not patentable, but in the biological 
sciences sector, to go back to your question of what is the value of my 
intellectual property in four years, I do not know. Now, I do not think that is an 
acceptable answer and it goes back to what I was saying [about] where we are 
in the cycle. When I look at the next generation of medicines that the folks in 
this room will take, it is not just the patents or the innovation on the pill or the 
product itself, it is the interface of potentially using artificial intelligence to get 
to more personalized medicine. If we are going to hit the Cancer Moonshot from 
former Vice President Biden, we will need more unique approaches to delivering 
medicine and we are going to need a robust, predictable Section 101 so we know 
what to invest in and that we can foster innovation in the next group of scientists 
coming out of universities and labs. While Congress is looking at Section 101, 
and I think is hopefully going to do good work there, [with respect to] some of 
the other patent legislation that is out there, we do need to make sure that we are 
not accidentally devaluing innovation in other ways, too. When we look at 
patents, we need to look at them as a whole. 
PATRICK KILBRIDE: I will just add a couple of points. First of all, I think 
worst case, the Director and his colleagues at the USPTO have provided a 
backstop to the erosion that we have seen, thereby preventing it from becoming 
an avalanche in terms of reduction of reliability of the system. Best case, they 
have actually started to take back some ground, and that is because getting the 
rules right is one thing, but you also have to get the rhetoric. Reliability depends 
in large part on market psychology; the market needs to see that the political 
system believes in the patent system, and with strong leadership at the USPTO, 
we have a much better chance of doing that. I start all of these conversations 
with the reminder that money is fungible, and capital is a coward, and if the goal 
of our intellectual property system is to allocate scarce resources to innovative 
activities, then we need the means to provide a path to return on investment for 
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those resources. That is what we have done so well in the United States, not just 
in the intellectual property space, but throughout our economy, as we have taken 
private sector resources off the sidelines and put them into circulation for the 
benefit of economic growth. But in the intellectual property space, that is 
tougher, because possession does not have the same significance that it does in 
terms of physical assets. We have to be able to define property rights and assign 
those rights so that people can possess knowledge, data, and information in the 
same way that they can plant and equipment. That is what we are working 
toward. That is what gives me confidence, because long term we have such a 
great track record in the United States of getting this right. 
So, what have we done well? First of all, we compete. Second, we enable 
failure. We empower risk, we provide rule of law, and then we make markets. 
One thing we have not done well yet is make markets for our intellectual 
property assets. That is why it is so discouraging sometimes to see these attacks 
on licensing models that prevent active markets for intellectual assets. As I said 
at the outset, I feel like we are just at the tip of the iceberg with this; if we cannot 
license and make markets for the patents and copyrights we have had for a long 
time, how are we going to do it for a set of much more intangible assets that are 
going to define corporate value in the future? 
DR. CARL J. SCHRAMM: I do not have much to add to this except after 
having done a huge amount of study of this at the Kauffman Foundation, we 
came up with a view that was not uniformly embraced by universities, and it 
basically was the free agent idea of how a principal investigator could get 
intellectual property discoveries into commerce. I think our estimate is that just 
having the university tech transfer offices involved creates a choke point with 
respect to this; it may delay the transfer of intellectual property into its first 
commercial formations by as much as three years. This is really a central issue 
because, and I am not a patent attorney so I cannot speak to this, from the outside, 
it looks like there is confusion as to who actually owns the intellectual property, 
and this issue was not around when the Bayh-Dole Act was passed. I think it has 
become an aberration from what the public policy intent was in terms of who is 
the owner. Now, I travel to visit universities constantly and it is actually quite 
shocking to go into a university technology transfer office. I have Johns Hopkins 
Medicine in mind at the moment and I see phalanxes of people, almost, it 
appears, as many people managing paperwork there as are actually principal 
investigators upstairs in the wet labs. With respect to the question, what is I-
Corps about, we do not have enough people upstairs in those wet labs, as I 
suspect you have a sense of based on your comments in the Teva situation. 
AMI PATEL SHAH: We are now going segue into another area. So, the new 
currency seems to be data as we all know. Companies are making money hand 
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over fist from our data. It also does not seem like the old intellectual property 
protections of copyright, trademark, patents, or trade secrets are working. So, 
what is going to be the new form of protection? Do we need a new form of 
intellectual property protection in this current age where data seems to be the 
new currency? I want to address these questions to the Director first. 
DIRECTOR ANDREI IANCU: Those are fantastic questions. First of all, 
folks are referring to this as the fourth industrial revolution, but whatever the 
name is, we are definitely on the cusp or the front-end of new technologies that 
are hugely transformative. AI, quantum computing, blockchain, biotechnology, 
and so on. I first want to observe that there is a lot of convergence going on in 
industry, and it goes in multiple different ways. You mentioned that in the 
biotech industry, there is huge convergence between the biology, the sciences 
themselves, and the computing industries. Much of the innovation there involves 
how you process with powerful computers interesting new statistical algorithms, 
for example, huge amounts of DNA data. There is a lot of convergence there. 
There is convergence between computing artificial intelligence and the 
automotive industries for self-driving vehicles, and on and on. As a side 
comment, there are folks who will say, “Well, do we not need two patent 
systems, for example, one for bio, one for tech?” I think there are many, many 
problems with that, one them being this huge convergence. 
Another question is what about intellectual property vis-à-vis all these new 
things. I will first observe that some of the problems we are having right now, 
they go straight to the heart of these most modern of technologies, and we’d 
better get our act together quickly because it is one thing to be losing a race with 
respect to technologies of old, but it is an entirely different situation when we 
are faced with the proposition of potentially losing the race to the technologies 
that are going to be critically important in the next few decades or century. 
Section 101 is just one example of where we need clarity when it comes to 
software processing, data processing, bioprocessing, biotechnology, and the 
like. It is critically important that we get our act together on these technologies 
of the future. Second, we need to ask, what forms of protection are there? The 
traditional forms are still available and, theoretically, if we get our act together, 
they should work on these new technologies. By the way, it is an odd situation 
that we have some people questioning the patent system when it comes to the 
processing and analyzing of data but not when it comes to the patenting, 
processing, analyzing, or manipulating of any sort of other material. The data in 
today’s world is the same as grain used to be in the agricultural world. It is the 
currency of today’s technology and the future, so we have to make sure that our 
systems operate as they should vis-à-vis these new types of technologies. 
Now, there are certain gaps that current intellectual property systems leave 
open. So, the data itself is not protectable by patents, copyrights, or trademarks, 
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but it is protectable through trade secret regulations, and a lot of companies are 
keeping their data sets proprietary and under heavy guards through trade secrets. 
That works for many of the data forms that are out there, but it is not necessarily 
a good thing because if you cannot share the data, it is very hard to train your 
artificial intelligence and machine learning programs. Other countries might 
have an easier path toward that. We also have to be very mindful of privacy 
protections and the like. There is a question as to whether, in addition to trade 
secrets, there is some other form of protection that might work here. Some folks 
are discussing data protection systems, the analogy being the data protection that 
exists in the biopharma area, where we have five years for small molecules, 
twelve years for biologic data and the like. It is not a perfect analogy, but it does 
raise a question as to whether we can develop some form of new data protection 
that incentivizes companies to share [data], potentially with some exclusivity, 
for a limited time with the benefit of getting additional protections. That would 
be something that Congress would have to act on, but we have to make sure that 
we address this issue because some countries, like China, do not have the same 
constraints that we have in the United States. 
COLMAN RAGAN: So, what the Director was saying is in the 
pharmaceutical arena there is an exchange in terms of disclosure. For example, 
you have a patent which discloses how you make and use something, you get 
your protection and your negative right that people cannot practice your patent, 
but you have taught the world how to make your patent. We have something 
similar with the data that gets generated. For example, if Teva has a brand-new 
drug, we generate reams and reams of data on toxicology, how a molecule binds 
to receptors, how safe that molecule is in patients and what indications it is used 
for, and so on. That is tons and tons and tons of clinical data. The exchange is, I 
get my five-year regulatory exclusivity if it is a small molecule, twelve years if 
it is a biologic, to sell my product, make my money back, and recoup my 
investment. In exchange, the generic companies or the biosimilar companies, 
they get to rely on my data, such as my safety data and my toxicology data, and 
bring a new product to market. They may also find some insight; they can run 
AI and see whether or not there is a new correlation in that data and a new way 
to use a product. So, there is this exchange that if we disclose our safety data and 
make it available to the public and anyone who wants to file a new application, 
then we get a regulatory exclusivity. I think that is what the Director was talking 
about, that there is a system in pharmaceuticals to share data, such that others 
coming later on can use it. That is how we use data in our industry, and it has 
worked. We have had a robust pharmaceutical industry and a robust generic 
industry because of this sharing of data and the sharing of our patents as well. 
PATRICK KILBRIDE: I actually think that is a great microcosm for the 
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broader discussion about trade secrets because what I see is an industry divide 
between those industries whose intellectual property lives in the product that 
reaches the market—the consumer-facing product—and those where the 
intellectual property lives inside the company within the platform but is not 
delivered to the consumer and so maybe it is not as vulnerable to disclosure or 
reverse engineering. So, you have seen that those companies whose intellectual 
property lives inside the house are more cavalier about patent protection, 
meanwhile, the other industries like biotech, pharma, the movies, music, they 
depend on actively enforced intellectual property rights. I think what we are 
going to see is more and more dependence on trade secrets as intellectual and 
knowledge assets form a bigger part of our corporate value and our productive 
assets because if people do not have to disclose, they really do not want to. I 
think we get ahead of ourselves a little bit when we talk about defining new 
rights before we have really done a good job of defining the assets. To me, that 
is the first thing. Let us define the different types of assets we want to protect 
and the categories that we put them in, then we can talk about what ownership 
means and what exclusivity means. Maybe then all we have to do in some cases 
is recognize that companies have these assets and allow them to capitalize them 
instead of expense them on their balance sheets so that they can leverage them 
to access financing, that might be enough. In the biotech case, of course, they 
are getting it two ways: they have to disclose their know-how in the patent 
disclosure and then they have to give away their trade secret and their company 
knowledge on the regulatory data side to prove their products are safe and 
effective. Meanwhile, the government wants to give it away. It would be akin to 
telling Google it has to submit its algorithm so that the government knows it is 
doing the right thing and then publishing it for everybody else to use. 
AMI PATEL SHAH: There is an economic impact to sharing this data, right? 
We have a robust pharmaceutical industry because of that. Professor, I want to 
ask you, what would be the economic impact if we were able to have this as 
opposed to companies keeping trade secrets? What if the data was shared and 
we were able to protect it? 
DR. CARL J. SCHRAMM: Well, it is a double-edged sword in a sense that 
we are constantly trying to push the volume of innovation forward, so every type 
of question like this has to be seen through the macroeconomic perspective of 
what are the incentives we are setting up for people? This is often missed by 
regulators. It is something we have been tangling with in Washington for thirty-
five years, in terms of what are the signals we are sending into the 
macroeconomic system with this regulation. I think one of the other panelists 
touched on it in terms of the issues we have with China, for example. We are 
constantly trying to figure out what is in the best interest of the economy in a 
global competitive situation, and these are examples that we are talking about in 
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terms of the data inside the pharmaceutical industry, but in a sense, [Mr. 
Kilbride] raised the question about Google and its algorithms. That is a topic 
that we actually never probe because it is just off the charts, but it has huge 
implications from a macroeconomic perspective, as well as for global security 
issues. 
AMI PATEL SHAH: I was not thinking of Google’s algorithm; I guess for 
me, when I was thinking data, I was thinking about Facebook. I give permission 
to Facebook to collect my data. They are then aggregating that data and selling 
it to third parties. That is the data I am referencing. People are profiting from it 
and keeping it internal and that is being done algorithmically or however they 
want to contain it, but that is not a proprietary for them. That is all of us giving 
permission to these third parties and these companies aggregating it using AI 
tools, using these new tools and then selling it and profiting from it. So, how 
does that work? Would that be something that we could protect? 
DR. CARL J. SCHRAMM: One of the places we are going to run into this 
that is going be very cumbersome is around AI and healthcare. We all have an 
interest in having every clinical intervention get stronger and stronger and we 
have been talking about this for years. We have been talking about how we are 
going to do artificial intelligence overlays on population data. But as we get 
closer and closer to it, it does raise issues, enormously complex issues, about 
patient privacy, individual privacy, who gets to know all this information. We 
are trying to solve this because the government is pushing forward several 
incredible agendas. One is we are going to have price regulation on a population 
basis. A subset of that is we are trying to solve medical problems now for social 
exposure and social diseases, and that energizes these questions about all kinds 
of intellectual property around food and the microbiome, what the nexus is to 
human health, and how we do this on a population basis and on an individual 
therapeutic basis. 
AMI PATEL SHAH: I have a follow-up on that; so, is the government staying 
ahead? Do you believe the government is staying ahead with all this movement 
that is happening within industry? Going back to my original question, I do not 
know if the regulators are staying one step ahead of what is happening within 
industry; I personally think they are miles behind. 
PATRICK KILBRIDE: I will say that I believe we are all behind the curve 
on data. As individuals, we were very slow to realize the value of the data that 
we have been disclosing; we want to get every new app and access to things so 
badly that we give away that data. But we are coming to realize that it has 
tremendous value both to the people that want to aggregate it and to us in terms 
of our privacy and our rights down the road. So, I cannot blame government, 
since I think everybody, except the people who are out there actively collecting 
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the data and seeing it, has been slow to respond. 
DR. CARL J. SCHRAMM: To touch on the question posed, I think the answer 
is very lumpy, and it has everything to do with industrial organization. For 
example, in the healthcare area, there are hundreds of thousands of startups that 
are trying to chew away a little bit at how you apply AI to specific data sets. So, 
there is this flurry of innovative AI in use there. We then move to other parts of 
the economy and there is already so much aggregation of data that there is no 
competition that is going to happen at all, take Google for example. So, I think 
the answer to your question is very lumpy, and it depends on a lot of the science 
inside these various industries and also their respective positions in the market 
already. 
DIRECTOR ANDREI IANCU: That is a very good point; I agree with the 
lumpiness. As a general proposition, when you do not have intellectual property 
types of protection available and instead you rely on secrecy, such as with data 
sets or even the technology that people are now beginning to keep secret because 
they are afraid that it is not patentable under Section 101, for example, as a 
nation, you slowly begin to fall behind. This is because it drives toward a 
concentration of resources. It creates bigger and bigger lumps, to use [Professor 
Schramm’s] words. 
Take the data example. The way to train machine learning and artificial 
intelligence programs is to run huge data sets through them over and over and 
over again, so that they can learn. Well obviously, the bigger the company is 
now, the bigger the data set they have now, and the better they can train their 
algorithms. I use Google, and just the other day, while I was signing in, it wanted 
to make sure that I was not a robot, and, to make sure of this, it asked me to 
identify which of the nine squares it provided had vehicles in them. I click on 
the correct squares and Google collects that data set. I am being a guinea pig for 
them while they are verifying that I am not a robot. Obviously, Google can do 
that with millions upon millions of people, and it can collect a massive data set, 
which it can use to train its artificial intelligence programs and make 
improvements. Now, imagine a small startup. Where does the startup get that 
data from? That is just a tiny example. But this makes it much more difficult to 
democratize innovation. One of the things that this country was so great at in the 
past industrial revolutions was democratizing innovation and spreading it all 
around, and this created this flurry, this explosion of innovation. We have to be 
careful that we do not put ourselves in a situation where we revert back to 
secrecy that ultimately drives toward the concentration of resources. I do not 
have the answer for the intellectual property, other than trade secrets, that would 
be needed vis-à-vis data sets. It is a highly, highly complex issue, as the 
Professor mentioned, especially with privacy and the like. Having said that, 
industry and government really do need to start having that discussion in great 
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detail. 
PATRICK KILBRIDE: If I may, the way to combat secrecy is to make a trade 
secret too valuable to hoard. When you create a right around an asset that allows 
its value to be transferred in the market, then there is a value to sharing it with 
others. Absent that ability to capture value and allow its transfer in the 
marketplace, the only answer is to hoard. 
AMI PATEL SHAH: That is a great segue to my next topic, which is going 
to be entrepreneurship. As the Director mentioned in his last statement, Google 
has access to all of these data sets, but what is a small startup to do? Where are 
startups getting this data? How are they going to get into it? I am going to start 
with you Professor Schramm, is this the best of times or the worst of times for 
innovation in the U.S.? I look at the situation and think, you could get a software 
engineer in India, you could get manufacturing in China, you could get design 
in Silicon Valley, you could put it together and you can go, and everything is 
readily available. Is that not a great thing for us? If it is, why are we being 
stagnant when it comes to innovation? 
DR. CARL J. SCHRAMM: The one thing we cannot quarrel with is it appears 
as if we are being stagnant. The good news is we are less stagnant than all of 
Europe and most of the rest of the world. Our great question mark is China. Also, 
when it comes to secrecy, we cannot really judge that. If you take all of that as 
a predicate, let us return to where we are in the United States. So, is this the best 
of times or the worst of times? We can get all this free programming, or almost 
free programming, in India. It is almost as if this is the best of times in the world, 
but what is the United States’ job in this? In a sense, our advantage has been that 
we can steer all those resources to an enterprise system in the United States that 
is very, very good at making new businesses. But even there, the data is 
becoming very, very worrisome. That is to say, we now start thirty percent fewer 
businesses than we did twenty years ago. So, if we were to look at the advertising 
about America, the words enterprise and entrepreneurship have sort of become 
descriptors of American culture. But in fact, if you dig down into the data, this 
may be very, very misleading and I think one reason is because we have become 
very formalistic in how we think about entrepreneurship. Thirty-five years ago, 
the man or the woman down the street starting a business was never described 
by his or her neighbors as an entrepreneur. The word was not in the discussion 
of governments. It was a person who started a business, and there were many 
more of them. There are estimates that almost fifty percent of veterans returning 
to the United States after World War II started businesses. It was not a unique 
feature of a person’s life, or our shared culture. 
Now, it is completely different. In fact, we have programs in universities that 
are set up to encourage people to become entrepreneurs. They also have majors 
2020] The State of Innovation in the Union 47 
in entrepreneurship, as if it was dentistry or accounting. I do not think we are 
doing very well there and there is no canon of knowledge. The last point I will 
make about this is, empirically, we focus on twenty-year-old college students. 
But many more people who start businesses have never gone to college, and that 
may actually be a cultural aspect of people who do not go to college; they may 
think that this is their way up. But to return to the age, the average entrepreneur 
in the United States is thirty-nine years old when he or she starts their first 
business. So, why are we selling this as a young person’s prerogative? 
AMI PATEL SHAH: The Executive Chairman of Blue Sources actually made 
a similar point in the earlier panel, that people who have started businesses are 
considered not qualified because they do not have a PhD. So, if that is the case, 
I will ask you Mr. Kilbride, what is the industry doing to curb this fail in 
startups? 
PATRICK KILBRIDE: First of all, what industry is doing mostly is helping 
to create the preconditions for investment and economic activity. There is a 
certain degree of regulation that helps make functioning markets. There is a role 
of government in identifying, establishing, and enforcing property rights. Those 
are pro-economic government activities. Then there are others where 
government gets in the way, where government is setting up roadblocks to 
economic activity. And so, as a business community writ large, we are trying to 
help policymakers see the landscape from a business person’s eyes and 
understand how these people can see a path to profitability from their small 
business, their innovation, whatever they may be involved in, or they can see 
insurmountable obstacles that will make them say, “It is better not to get into 
this in the first place.” That is the real danger; it is stagnation where people are 
saying, “I am not going to take a risk.” So, we want to create those paths for our 
small business owners or large business owners [that allow them] to take risks. 
Historically, we have done that in the United States better than anyone else, and 
we cannot forget how we got here. 
DIRECTOR ANDREI IANCU: To put things in historical context, when the 
country was first founded at the end of the 1700s, we began with nothing other 
than an idea, some hard-working people, and amazing natural resources. But 
there was nothing in the beginning, and we were going up against a thriving 
world. The British Empire was at its peak. We were the new kids on the block. 
We have to be careful not to get complacent so that we end up in the position 
that Great Britain was in at the end of the 1700s; they thought they were at the 
top of the world and that they could stay there forever. We had hungrier people 
who came around, who were more motivated with a great need to get the country 
off the ground, and we did amazing things. Now, we have to be careful not to 
overregulate and not to have a system where we are twisting ourselves into a 
pretzel on every single intellectual property issue, and many other similar issues. 
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Especially since, in the meantime, you have countries like China and many, 
many others, including small countries that are going all-out to compete with us 
and to outdo what we are doing. My only point is that just because we have been 
and currently are at the top of the technological world, there is no guarantee that 
we will always be there. There are many examples in history where leaders 
relinquished their leadership positions, and we have to be fully conscious not to 
do that. 
COLMAN RAGAN: I would like to highlight a statement that my football 
coach used to make: “When you are through improving, you are through.” We 
need to keep improving. And I also want to go back to one of the earlier 
statements questioning whether technology is getting caught up in the university 
tech transfer. I am not sure what the answer is, but in the biotechnology space, 
there used to be an ebb and flow between merger and acquisition and then out 
of the ashes of merger and acquisition would be many new startup companies. 
In this last round of innovation however, I was not seeing that as much. I do not 
know what is causing this and why this next round of innovation is not 
happening, but we do need to keep pushing forward if we want to stay on top, at 
least in biopharmaceuticals. 
AMI PATEL SHAH: So, it sounds like we are not seeing these small 
companies come through, and it seems like in the last decade I have seen that 
large companies are not innovating. Their innovation involves buying small 
startups after they get to a certain point. In fact, I spent a decade at a large 
multinational company where we bought many companies. I know this is more 
prevalent in the bio and pharma areas, and not as much in tech. But, if we are 
not seeing that cycle that we are all so used to, then where are we in five years 
and what can we do to curb that? Also, what role will the government play in 
this? What role will the Patent Office play in protecting and helping these small 
companies so that they can grow instead of waiting to be acquired? 
PATRICK KILBRIDE: I will go back to the return on investment initiative 
green paper that NIST helped lead on an interagency basis. The Chamber of 
Commerce’s comments into that process were that government funded research 
is good, private sector funded research is good. It also wanted to understand the 
different objectives from each and the different roles of each. The government 
has a role in pushing the economy in certain directions, such as by giving 
strategic nudges. We have economic, social, military, and broader strategic 
interests, and government funding helps channel academic research, pure 
science into those areas where they see a need and want an outcome. Private 
sector entities and universities generally pick up where governments tend to 
leave off, that is, at the applied science stage, R&D. They focus on how you take 
a basic discovery and turn it into a usable product. Where I see real value from 
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this initiative is in how it helps to define that process that comes after the 
government funding has left off, and before a product reaches the market. What 
are all the go/no-go decisions that have to take place between that university 
researcher who may want to leave and create the startup, the university that 
wants to get the revenue dollars and the recognition from having that tech 
transfer, the financer that might come in and wants to understand what the 
playing field looks like and whether they can make a return on investment, and 
so many others? We need to pull back the veil that makes innovation seem like 
an “aha!” moment and show it as a whole series of rational economic decisions 
where players like you and me will not say yes unless the conditions, the policy 
and economic conditions, support that decision. We need to pull back the veil 
and help all of our policymakers see innovation for what it is. 
AMI PATEL SHAH: For me, for return on my investment, for my fund, if 
there is no patent protection, I do not loan money to the company. That happens 
in the diagnostic space as well as in the software, AI, and quantum computing 
[spaces]. I need that protection because I want to make sure that there is 
protection in this startup to keep them afloat. And so, it is a battle. This is why 
if in the next five years all the technologies are going to be in data and software 
and we do not have intellectual property protections, I am a bit concerned. When 
I was at a large company and I was looking to acquire [companies] while in-
house, my whole approach was, “Well, if I buy it but there is no protection in 
that little module that I am going to then put into my overall big system, is it 
worthwhile for me to purchase it?” 
PATRICK KILBRIDE: There was a terrific article in Intellectual Property 
Watch about a year ago. They interviewed David Hanson, the CEO of Hanson 
Robotics. He talked about his intellectual property portfolio in terms of the top 
10 percent most valuable assets being protected by patents. But he also talked 
about a range of licensing deals, trade secrets, open source, and he even talked 
about open trade secrets where he said, “There are some things that I could 
publish a manual on, and other people still could not do it because the artistry, 
the experience that we have gained within our company over many years allows 
us to apply this knowledge in ways that other people simply are not capable of.” 
So, I think we have to extend our understanding of intellectual property to 
encompass that broader set of assets and portfolios. We should not always look 
down on trade secrets, but instead try to minimize the conditions under which a 
company would try to hoard their trade secrets. 
DR. CARL J. SCHRAMM: So, the question we started out with was, “Where 
are we headed with all of this innovation or lack thereof?” Well, there is a key 
here that we do not understand at the macroeconomic level and it is that our 
economy has been reshuffling itself for twenty years. We have fewer publicly 
traded companies. We have much more concentration in big companies. As an 
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adjunct to this phenomena, this particular city has come to see itself as helping 
everything along. I live in America, so every time I approach the District of 
Columbia, I think, these are the folks who are going to change things. So, in fact, 
the reason I raise this is because in a previous panel we saw, I think in the green 
paper, this discussion about this is America’s startup fund. Well, half of me 
smiles with that because I am an investor and the other half stops my blood 
because the government is picking winners. How has that gone? Not that well. 
What we are facing here is huge companies that actually enjoy great preservation 
of their respective competitive positions. The government and various 
administrations have done great deals to preserve those situations, especially in 
recent administrations, both Republican and Democrat. This is what Paul Ryan 
used to speak of as crony capitalism. To the extent we have that in place, that 
dampens innovation. We do not have a critical discussion going on in the United 
States about how we preserve our role in the world. As the Director rightly 
pointed out, we used to be incredibly vigorous in the face of enormous global 
resistance. We were the upstart. We had no money. We had no venture capital. 
Nobody was doing USAID to the United States. What do we do now? I think we 
need to have a national discussion that sounds something like an offensive 
enterprise strategy, where the country actually understands all these difficulties, 
that innovation is our future, and if we do not reshuffle, reorder, change the way 
our industrial organization is in place now, we are not going to triumph in the 
long run. 
AMI PATEL SHAH: I want to now ask the Director some questions. The 
Patent Office has various programs to encourage entrepreneurs to file patents 
and to get their technology out there. Could you talk about some of the programs 
that you have and what you see coming? Also, what can the Patent Office do to 
encourage entrepreneurs to become more active with the USPTO? 
DIRECTOR ANDREI IANCU: First of all, the vast majority of patents in the 
USPTO are being filed by large corporations. But we do have a program for 
small entities that is congressionally mandated, through which we give a 50% 
discount. For micro entities, which include very small entities, solo inventors, 
and the like, we offer another 50% from that. However, I do not think folks are 
making their investment decisions, their innovation decisions, or their decisions 
of how to spend their R&D dollars based on the filing fees at the Patent and 
Trademark Office. The much bigger questions revolve around the things that 
have already been discussed and whether the intellectual property that we do 
issue is something that they can rely on. Can they get the intellectual property, 
and can they rely on it once they get it? By the way, with respect to the question 
about where we are going in five years, it is not a big mystery. I believe patent 
filings are a leading indicator. We can see where the technologies of the future 
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are, where they are concentrated, and what countries are doing what. 
I will give you some rough statistics. With technologies of the fourth 
industrial revolution, or the technologies that China identifies in their Made in 
China 2025 plan such as robotics, artificial intelligence, biotechnology, and the 
like, the rate of increase in patent applications in those technologies that matter, 
by American companies filing at the U.S. Patent Office over the past decade, 
has been 3% a year. This is not bad and is somewhat in line with the growth in 
gross domestic product and the like; it is not really all that surprising. In China, 
looking at Chinese companies filing at the Chinese Patent Office, the rate of 
increase in those same technologies is 24% a year, year over year, and we do not 
see any slowdown on their side. In addition to that, China is not the only country 
that is innovating at increasingly high rates. Medium countries, like Korea and 
Japan, and small countries, such as Singapore, Israel, and the like, are doing the 
same. The competition is truly global, and our 3% is not going to stand a chance 
if we do not up the ante. By looking at the filings today, we know where we will 
be in five years if we do not change the trajectory. 
So what can the USPTO do? We must, first and foremost, steady the ship 
when it comes to intellectual property protections. Section 101 is just one 
example. But my view is we know the answer and what to do, so let us just get 
it done. Steadying this ship is not that complicated, and we have done it at the 
USPTO. Once we have a steady ship when it comes to the laws, investors will 
know where to invest and that they can rely on the system. Second, what we can 
and should do is broaden the innovation ecosystem. We cannot compete with 
China in terms of population. We need a higher percentage of our own 
population to innovate. Demographically, we must expand. For example, more 
women need to be brought into the system. Currently, only 12% of inventors in 
the United States are women, and that is way too low. We need to also broaden 
geographically. There are many areas within the United States that are not 
patenting much at all. Economically underprivileged communities are also not 
patenting much. We simply need more hands. In fact, we need all hands on deck. 
I think the USPTO and other entities can lead the discussion, but ultimately, it 
is industry. Industry and academia need to take the lead on this, and the 
government needs to get out of the way. 
AMI PATEL SHAH: To the members of industry, how is the industry going 
to [accomplish this goal]? 
COLMAN RAGAN: Well, I guess I will take it from the biopharmaceutical 
side. In the industry, I go back to the professor’s statement from earlier about 
there being too many suits and not many people at the wet lab. I think back to 
when I was a researcher in the late 1980s and early 1990s, there were more 
people at the bench in the industry conducting research. So that means we need 
to be pulling more young scientists out of schools into the companies, not relying 
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on them finding funding. I think about this because I just did my high school’s 
fundraiser, and we did a lot on getting more funding for science, technology, 
engineering, and mathematics (“STEM”) classes and getting high school kids 
involved in innovating. As an industry, we probably do need to foster the next 
generation of scientists. Then, for the scientists that come into our companies, 
we need to foster that organic growth. We need to foster them to do the wet 
science at our companies rather than look to buy it somewhere because if we 
plant that seed, perhaps it will grow. 
DIRECTOR ANDREI IANCU: The fostering of STEM innovation is the 
answer for the next generation. It needs to start at the youngest ages possible. It 
needs to start in fifth grade at least, and industry has a huge role to play here. 
There are schools across the country that are almost not participating at all, or 
very minimally, when it comes to science or engineering or mathematics 
curriculum and development. This happens for several reasons. First and 
foremost, lack of resources. Second, they do not have enough role models. 
Industry can participate in their local communities at the youngest ages with 
financial help, role models from their own ranks, and in combination with the 
academic institutions. I think if we have a national effort on this, we can move 
the needle. 
AMI PATEL SHAH: Both of these issues are near and dear to my heart. I am 
a mentor in STEM, and I grew up in inner city, Detroit. The schools are not that 
great, so I have been an active participant in the Detroit school system and 
STEM. I am also the mother of three daughters. One is an engineer, another is 
in engineering school, and one works upstairs in policy. Both steps combined, I 
see the difference we can make. I can see the need. And if we leave out fifty 
percent of our population over the next five years, then we are never going to 
play catch up no matter who we compete with. Rather than comparing ourselves 
to other countries, I think we need to compare ourselves and realize we have 
fifty percent of the population that needs to be included. Not only that, but there 
was a report released yesterday detailing where most of the patent filings are 
happening by state. If you look at the states, it was directly correlated to where 
venture capital funding is going.17 It is going to states on the coasts and to very 
few states in the middle of the country. It is going where the biotech and tech 
companies are located. But, you are telling me there is no innovation in the 
middle of the country, north and south, anywhere else, and that those states are 
not represented? Also, I do not know if those areas know you can patent certain 
                                                          
 17 What Is Venture Capital?, INVESTOPEDIA (Oct. 13, 2019), 
https://www.investopedia.com/terms/v/venturecapital.asp (defining venture capital as a 
“form of private equity and a type of financing that investors provide to startup companies 
and small businesses that are believed to have long-term growth potential”). 
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technologies. I do not know if the folks in the agricultural world know that you 
can get certain patents. So, I think we do need more education, but how do we 
get there? What role can the Patent Office play in this, and what role can the 
government play? Also, what role can industry play? I think the industry has the 
largest reach, so what can it do? 
PATRICK KILBRIDE: In the past generation or two, half of our capabilities 
were left on the sidelines. We were not utilizing the knowledge, the know-how, 
the perspective that women bring to the workforce. But today, to a much greater 
degree, we are seeing women fully integrated into the workforce in a way that 
represents a competitive advantage for the United States because we are ahead 
of the curve. We have not yet seen that in our political system, but we will get 
there. I think at the same time that has happened, we have had a cultural shift 
that has not put as much value as we need to on those academic disciplines in 
the STEM areas that lead to innovative competitiveness. This is an area where I 
think our women have to say, “No, we are not going to follow men into the 
workforce. We are going to forge our own path. We are going to set a different 
set of objectives.” Let women define where innovation takes America in the 
twenty-first century. 
AMI PATEL SHAH: I want to follow up on this; women could do this, but it 
is also an issue of funding, right? We need to look at the amount of funding that 
goes to women led companies. The funding to women led startups is 2.2 percent 
by the National Venture Capital Association. It is usually the venture capitalists 
and the investors that are asking folks to get the patent protection for their 
investment that they are making, but if these are the companies that are not 
getting it, then that is why we are seeing the lack of them from the women’s 
study that the Director initiated. There is a whole slew of issues there, but I know 
people have questions. I am going to open it up to some questions, and then I 
want to end with a last set. 
AUDIENCE MEMBER 1: First, I have a comment. We were talking about 
the Bayh-Dole Act and saying that there [are] a lot of people in tech transfer 
offices and so forth. That is really the exception. For example, at Syracuse 
University, there are two people in the tech transfer office. That is much more 
common than what we see at Johns Hopkins where there [are] seventy-five 
people. So, I would be hesitant to want to change Bayh-Dole for that reason. 
Also, I think it is important that whenever Bayh-Dole comes up, that we also 
remember that it has really been the driving force of startup companies in the 
tech sector, including almost ten thousand startup companies with a hundred 
thousand people employed. It is one of the most successful pieces of business 
legislation ever passed since the end of World War II, and that is something to 
think about. 
The question is to the Director. About this time last year, you were saying that 
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we all needed to be concerned about Section 101 and Congress needed to be 
concerned about Section 101. We all seem to have a part to play and now 
Congress is kind of doing their thing, but I have not heard you say anything 
about whether you support what Congress is doing or do not support what they 
are doing. I know there is no language there really to support, but do you still 
feel that there is a need for legislation? I know you said a little bit earlier, but 
then it sounded like you were still holding out some hope for the courts, and I 
do not know exactly where you fall on that. 
DIRECTOR ANDREI IANCU: In the end, when it is all said and done, all 
three branches need to be rowing in the same direction on something like Section 
101. The courts need to be part of this system for several reasons. Let us assume 
that there is legislation passed tomorrow redefining Section 101. It will 
immediately be challenged; it will immediately be subject to interpretation; and, 
in fact, years of litigation will ensue, and there will be a debate as to what each 
and every new word means in the new legislation. If the courts continue to think 
along the same direction, forget the words of any particular statute, but if they 
think policy-wise that it is their job, for example, to say that diagnostics are not 
patent-eligible in the United States and that we are not in the business of giving 
them patents, or to say that certain computer algorithms are not eligible, they 
can almost always find ways to interpret any word in a statute. Now, I suppose 
you could eliminate Section 101 completely or something, but I suspect that no 
matter what this new statute says, you are going to have a long period of debate 
as to what it means, and it is important for the courts to go, generally speaking, 
in the same direction, if possible. But that is only if a statute gets passed 
tomorrow or very soon, which, as we know, is not very likely. Who knows when 
it is going to come out? In the meantime, we have a patent system to run. 
Every day, we see thousands of patent applications. Every day, we must make 
decisions at the Patent Office. Every day, inventors, patent owners, and the 
public need to make business decisions based on the patents and applications 
that are out there today, tomorrow, next week, next month, and so on. What are 
we supposed to do now and until this new statute passes, if it ever passes? The 
answer to that immediate problem is that we have an approach at the USPTO 
which is working, and it would be great if the courts let us do what we are doing. 
That addresses the problem now. That is not to say that legislation is not needed. 
It may very well be, and we need to work on all options. I was on a panel with 
Judge Michel a couple of weeks ago, and there was this back and forth over what 
is the best approach. Is it through the courts, or is it through Congress? At the 
end of the day, the judge said, and I agree, that we need an “all of the above 
approach.” 
COLMAN RAGAN: I would just like to echo some of the Director’s remarks. 
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As a patent litigator, he is right. If a new statute gets passed that is a fair 
employment act for someone like me, we will absolutely be litigating every word 
in it. But to circle back on some of the other issues, through litigating patents I 
get the chance to interact with a lot of the federal judges and I do sense some 
confusion right now. I think every time a judge gets more confused he or she 
makes the Director’s job to try and implement that new piece of case law into 
the way people at the Patent Office review the patents even harder. I do thank 
the Director for all the hard work he is trying to do to make it a little bit more 
certain for us. I also would agree that it is going to take the courts grappling with 
the issue along with the administration trying to get the right guidance, and it 
may end up in legislation. 
DIRECTOR ANDREI IANCU: I do want to emphasize that as I have said 
before, I do not see any indication right now from the courts that they are about 
to change course. It is basically status quo for them, the way it has been for the 
past few years. But, again, if that is the case, then legislation becomes necessary 
and not just optional. 
AUDIENCE MEMBER 1: Since you were once in our seat not too long ago, 
what do you think people like us should be doing in this uncertain time? 
DIRECTOR ANDREI IANCU: Do you mean as practitioners or as 
advocates? 
AUDIENCE MEMBER 1: I was leaving it open so you could answer the 
version of that question you might want to talk about; you could answer it from 
the perspective of practitioners seeking patents or litigators litigating patents. 
DIRECTOR ANDREI IANCU: As practitioners, I believe our guidance is 
fully compliant with the case law to date. What does that mean? If our guidance 
is followed correctly by the examiner and the applicant in the Patent Office, I 
believe a patent will issue that should be sustained by a court applying the court 
cases to date. I think practitioners have to be fully aware of all the case law just 
like they have been until now. Make sure you follow the case law and you can 
apply our framework, which is basically a synthesis of the law but in a more 
clear and systematic way to achieve more consistency and practicability. When 
you are in the Patent Office, follow the guidelines, and if you follow the 
guidelines you will end up with the correct results. Always keep your eye on the 
cases though, and I think you will end up in the right place. 
As advocates in the policy debate, which is a very different question, I think 
you should stay involved. I think it is critically important for everybody to hear 
how significant this issue is. It is important to industry, and it is critically 
important to inventors and patent owners, but it is also important to the public 
in trying to understand what patents are out there so that they can invest in or 
invent around them. In my opinion, this does remain the most important 
substantive issue of patent law, and we need all voices to be heard and to be 
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made known so that the legislators understand that this is an important topic to 
resolve and that the courts hear us out. And I do not think this is a mystery. I 
mean, it is not just me saying it as the current Director—you have past Directors 
at the Patent Office saying it, you have past Judges of the federal circuit, past 
Chief Judges of the federal circuit, leading practitioners, everybody in the 
industry, saying generally the same thing. Now, not every everybody agrees with 
the exact outcome of each particular case, and that is fine, but everyone knows 
that the situation that we have from the case law right now is untenable, and it 
needs to be resolved. 
AUDIENCE MEMBER 2: This is for anyone on the panel, but I think it is 
probably more directed to Mr. Colman Ragan. Tomorrow there is a hearing on 
the Senate side dealing with drug pricing and I am sure you are aware of that. I 
have been told by people on both sides of the aisle that if anything on patent 
issues passes this year, it may be something along those lines. I do not quite 
understand the implications with respect to patents, and I am steeped in patents, 
but I have been reading articles where there seems to be aspersions cast on the 
fact that Humira had over a hundred [patents] associated with it, sort of 
allegations of a thicket. There have also been aspersions cast on protecting 
patentable improvements over original drugs and I want to know what you think 
is going on and what you are all are thinking about this particular issue? 
COLMAN RAGAN: When you say this particular issue, I am going to take 
that as sort of the basket of various legislation in the pharmaceutical arena aimed 
at patents and pricing. When I look at all of them including this hearing on 
thickets, I worry that there is this underlying current that, at least in the 
biopharmaceutical industry, patents are bad. Whether you look at the patent 
settlement legislation proposals that seem to say patents are bad, or certain types 
of patents should not be granted in the pharmaceutical industry, or you should 
not use the mechanism, or you should not get a patent thicket, I worry that in 
proposing some of these pieces of legislation, you will have the opposite effect 
on drug prices and they will be drive up. Especially, if people cannot settle cases 
or if you mess with the mechanisms of the Hatch-Waxman Act,18 which is how 
generic drugs come to market. But in particular, with respect to this hearing, I 
guess I would say I am not sure what a patent thicket is. I know that there are a 
lot of patents associated with Humira and I worry about the situation where we 
tell people in the biopharmaceutical industry, “You cannot get a patent after your 
first one, so do not innovate anymore. It is anti-competitive, do not innovate, 
                                                          
 18 Hatch-Waxman Letters, U.S. FOOD & DRUG ADMIN. (July 19, 2018), 
https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-letters 
(explaining that the Hatch Waxman Amendments establish the pathway to approval for 
generic drug products, allowing entities to submit an abbreviated new drug application). 
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because if you get another patent, we are not going to let you have it.” I worry 
if we go that far, and I do not think it will help drug pricing. My answer to a 
patent thicket, assuming that it exists, is we have a robust system of courts and 
one can go through the courts and settle his or her patent litigation and license 
the patents. That will bring the next generation of products to market and that 
will allow the innovator to move on to the next disease state. So, when we look 
at pharmaceutical legislation as a whole, I worry that we devalue patents and 
devalue innovation. I understand that drug pricing is a really hot issue right now. 
I just think patents are not necessarily the thing that drives drug prices and if we 
attack patents in the pharmaceutical sector, we might end up really hurting 
innovation over the next four to five years. 
MISSIONARY RANGE: I am the intellectual property owner, the copyright 
author of “All Lives Matter,” which was a sermon. I am a missionary. My 
intellectual property is a copyright and just as we spoke about devaluing patents, 
devaluing copyrights is occurring at this moment. As we all know, many people 
have seen “Black Lives Matter”; they have seen the protests, the trademarks, and 
all of the different organizations and people calling themselves leaders. I do not 
know any of those people, and so I want it to be clear that when I move forward 
with my building on my property, I have a clear space, meaning that there are 
no counterfeits out there devaluing the brand. I am a missionary and my work is 
actually holy. My work is “All Lives Matter” and “Black Lives Matter,” 
together. Meaning that “All Lives Matter,” the name of the sermon it came from, 
and “Black Lives Matter,” “White Lives Matter,” “Blue Lives Matter,” etcetera 
are examples in that sermon. They all come from the same work, so how do I 
stop Wikipedia from publishing and defaming the work? How do I stop 
Facebook from letting people have “Black Lives Matter” organizations that have 
no people in it that are collecting money? How do I stop people from saying, 
“We have a trademark on your work”? How do I stop people from saying, “I am 
a co-founder because I put a hashtag on your copyrighted work”? And so, 
because my work was pre-verdict, meaning before the Trayvon Martin verdict, 
how do I enforce [my rights] without the help of intellectual property 
organizations, the copyright office, and the USPTO? I stopped by there, I told 
them to cancel all the trademarks as a copyright directive, and I showed them 
my identification, my copyright, and everything. So that is my question: How 
do we protect the brand, before we have actually started building upon it, from 
other people who are building on the work and running away with the idea but 
taking it in a moral direction that we are not sending it in? 
AMI PATEL SHAH: Let me see if I can help address this. So, you are saying 
you have a copyright or a trademark on a particular asset and you are trying to 
protect that? 
MISSIONARY RANGE: I have the copyright, yes. 
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COLMAN RAGAN: I guess I will start with the fact that I do not think I can 
give legal advice in this setting because I have an ethical duty to Teva 
Pharmaceuticals. I want to make that clear. And you have asked this big question 
about policing your intellectual property and how you do it. I mean there are 
various ways and I do not know if any of the other panelists want to address that. 
PATRICK KILBRIDE: At the Global Innovation Policy Center (“GIPC”) we 
have a mantra: innovation happens everywhere. But the fact is it is based on the 
idea that some of the most innovative people in the world are children playing 
in the street. They will always come up with a new, creative way to entertain 
themselves. The fact is innovation does not happen on a transformative scale 
everywhere in the world. The reason is that those intellectual property principles 
are not enforced in the same way everywhere in the world. We have a research 
set at the GIPC that looks at fifty of the world’s major economies and compares 
across forty-five different indicators the ways intellectual property is protected 
from one country to another, and they are vastly different. If you go to another 
market, you cannot necessarily rely on the same protections that you can get here 
in the United States and vice-versa. That is equally true when it comes to the 
creative space rather than the innovative. One of the benefits of our system is 
that it has allowed authors like you to invest in themselves so that they can make 
livelihoods from their creative works. It is not just a hobby; it is not something 
they do in addition to their day jobs because they love it. There were singers and 
there were writers and there were poets long before anybody coined the term 
intellectual property, but they were not able to dedicate themselves to their 
works and earn livelihoods or the respect of their communities in the same way 
that they can today because today we protect intellectual property. And there is 
a mindset out there today that the digital economy is different and that different 
rules should apply. Well, we should reject that. When we sent a man to the moon, 
when we put planes in the air, it was not because the laws of physics stopped 
applying, it was because we learned to use those laws to our advantage, and the 
same is true in the economic space. Just because we have created this 
opportunity to have digital products and digital exchanges does not mean that 
the rules of supply and demand suddenly changed. They still apply today, and 
we have to be able to reward creators like yourself if we are going to encourage 
you to be creative. So, this is a huge problem. There was a White House 
Roundtable that I had the privilege of participating in along with Director Iancu 
a week ago where they were very focused on finding solutions to this issue, but 
it is not a problem that has been solved yet. All I can do is encourage you to be 
outspoken, to speak up for your rights where they are implicated, and to 
contribute to conversations like this one so that we can make sure that your 
future as a creator is protected. 
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AUDIENCE MEMBER 3: Hello, my question is about standard-essential 
patent (“SEP”) licensing. Given that we just had the Apple-Qualcomm 
settlement, I wanted to get your thoughts on whether in the next five years you 
expect to see some sort of fight similar to that. Do you think the way that case 
ended has really changed the landscape for licensors and licensees of SEPs in 
the United States? 
DIRECTOR ANDREI IANCU: Thank you for that easy closing question. 
[Laughter.] 
DIRECTOR ANDREI IANCU: I do think standard-essential patents19 are 
important and that they are going to play an increasingly important role as we 
move forward. In general, standards are increasingly more important if you look 
at 5G, for example. It is a huge area of new technology, with many standards 
being developed. With all the new areas of technology, including autonomous 
vehicles needing to communicate with each other and so many others, we are 
going to see an increasingly important role of standards-based technology and, 
as a result, standards-based intellectual property. Whatever impact the Apple-
Qualcomm settlement has, I do not know that, in particular, it is going to drive 
the debate one way or another, but in the end, the bottom line is that standards-
based technology was part of that major matter. It was a global dispute, and it 
ended on a voluntary basis. We will see how it progresses overall. All I can say 
is that we have to make sure that whatever policies we have in this country, 
whether they come from the standard side of things, antitrust and the like, or the 
intellectual property side of things, we need to have a balanced system that does 
not incentivize “bad behavior” one way or another. We want to make sure that 
if we have policies in these areas, we have policies that drive toward good faith 
negotiations so that we can increase the amount of innovation in this country 
that goes toward standard technologies and the amount of implementation of the 
standards that are being developed, hopefully, in this country. The policies that 
we have need to be balanced and fair to both patent owners and implementors. 
AUDIENCE MEMBER 3: Just a follow-up then, the Department of Justice 
(“DOJ”) has sort of changed its stance based on the SEPs injunction policy. Do 
you see eye to eye with that or perhaps you can talk a bit more about the U.S. 
perspective on the SEP policy changes at the DOJ? 
DIRECTOR ANDREI IANCU: You are talking about the 2013 policy 
statement between the DOJ and the USPTO on fair, reasonable, and non-
                                                          
 19 Gene Quinn, Standard Essential Patents: The Myths and Realities of Standard 
Implementation, IPWATCHDOG (Feb. 4, 2019), https://www.ipwatchdog.com/2019/02/04/ 
standard-essential-patents-myth-realities-standard-implementation/id=105940/ (describing 
standard essential patents as those patents which are necessary for the implementation of a 
standardized technology and which exist to protect innovation that takes extraordinary effort 
to achieve). 
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discriminatory (“FRAND”) encumbered standard-essential patents. The DOJ 
withdrew from that in December. The USPTO and the Department of Commerce 
are looking at that right now, and, hopefully, we will have something to say in 
the coming months. 
AMI PATEL SHAH: We have time for one more question. 
AUDIENCE MEMBER 4: This question is for anyone on the panel. Do you 
think that the current interpretation of the eBay decision20 by the federal circuit 
and the injunction rules are working for patent owners these days or not? 
PATRICK KILBRIDE: I will make a very brief comment and let the technical 
experts speak. I will simply say that to me, damages are to injunctive relief what 
a mop is to being able to repair a hole. 
[Laughter.] 
COLMAN RAGAN: I would say that for my sector, which is operating under 
the Hatch-Waxman Act where the injunction is automatic under the way it 
happens, it is an injunction against approval, we do not really deal with eBay all 
that much. It is really not much of a driving factor in our sector. 
AMI PATEL SHAH: As a closing, professor, from an economic perspective, 
what is the good, the bad, and the ugly for the next five years in entrepreneurship, 
the digital era, patents, everything we have discussed today. What are we doing 
right, and what are we doing wrong? 
DR. CARL J. SCHRAMM: Well, I am particularly optimistic, largely because 
the underlying economy is surging and that will change things. For example, I 
have just been looking at a lot of data here. There is actually starting to be a 
decrease in the number of incubators in place. I think that is great. I have looked 
at incubators as basically a staging area for people who could not enter into the 
job market. I think that as a labor economist, that is the way I have seen it, and I 
think it actually operates that way. If you look at the statistics in terms of what 
comes out of those places, almost nothing comes out. So, what that means is that 
we have a whole group of kids, because they are principally youngsters who go 
stall their labor market entry, starting to go into the labor market; that is one 
thing. Second, the demand in big companies is really surging for smart kids, and 
I am sure you see that. That is great because it is big companies that are really 
the incubators. Our most productive entrepreneurs come by accident, in mid-
career, out of big companies where they were schooled in everything that you 
need to get an MBA, but more importantly where they were schooled in all the 
techniques, the know-how that was spoken of before. And they see the edges of 
where the innovation has to go; that is our innovator class. Somebody in the first 
panel talked about it in terms of line extension. Line extension is central to this 
                                                          
 20 eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006). 
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because it is line extension that creates the companies where the innovation is 
begged for, and the scientists then follow-along. And so, I am particularly 
optimistic about it. The cloud that hangs over all this is where we stand with 
China relative to all these questions. As the administrator said, we have a 2020 
deadline, 2025 declaration, and 2041 is the centenary of Mao’s takeover by 
which China hopes to be the world’s hegemon without a war. That is a simple 
way to say we will have an innovation contest with the Chinese, and they aim to 
displace us. That is a big, big issue. 
AMI PATEL SHAH: It is a big issue in patent law as well, especially since 
they are patenting all the technologies that we cannot patent under Section 101, 
but I will leave it at that. Thank you, everyone. For our closing remarks, to my 
good friend, Judge Rader. 
[Applause.] 
JUDGE RANDALL R. RADER: I have enjoyed an excellent presentation 
today from two panels. I would like to invite us to make two comparisons. In the 
early 1980s, in the legislative arena within a few years we had the Hatch-
Waxman Act, the Bayh-Dole Act, and the creation of the federal circuit, all with 
a mind to increasing innovation policy. In the judicial arena, the Supreme Court, 
perhaps responding to the political dimensions of what Congress was doing, had 
the Chakrabarty21 and Diehr22 decisions which opened up technology to 
software and biotechnology. Now, compare that with the last decade or so where 
in the legislative arena the thing we have to focus on most is the creation of the 
PTAB, which prides itself in eliminating between 60 and 80 percent of the 
patents now important enough to be in litigation. In the judicial arena you have 
the eBay,23 Lexmark,24 Alice,25 Mayo,26 and Myriad27 decisions, all of which 
have severely handicapped the innovative capacity of the United States. That is 
one comparison, the 1980s to our current era. 
Now, I would like you to compare our current era to the great challenge which 
we face according to our second panel, in particular our esteemed economist on 
that panel. In China, in just the last three weeks to a month, you have seen the 
creation of a central appellate court like the federal circuit. You have seen the 
announcement by the Standing Committee of the National People’s Congress of 
the revision of their trade secret law to enhance civil penalties and ensure that it 
is used more effectively. You have seen a revision of their trademark law to 
eliminate the cybersquatting problems and strengthen that dimension of 
                                                          
 21 Diamond v. Chakrabarty, 447 U.S. 303 (1980). 
 22 Diamond v. Diehr, 450 U.S. 175 (1981). 
 23 eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006). 
 24 Impression Prods. v. Lexmark Int’l, Inc., 137 S. Ct. 1523 (2017). 
 25 Alice Corp. v. CLS Bank Int’l, 573 U.S. 208 (2014). 
 26 Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012). 
 27 Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013). 
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intellectual property to focus it on actual use. You have seen in their judicial 
arena that statistics show the nation in the world where you have the best chance 
of winning as an alien litigator is China, not the United States. Looking at those 
two comparisons, do we not have an even greater imperative to take some of the 
advice we have been given here today in both the legislative and the judicial 
arenas and see if we cannot revive the spirit of the 1980s? Thank you very much. 
[Applause.] 
JEFFERY P. LANGER: Thank you all for coming. That concludes the 
program. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
